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ABSTRACT

Tau is a protein which regulates microtubule stability and is heavily involved in
axonal transport.

This stability is dynamically controlled in part by over 40

phosphorylation sites across the tau protein which allows for binding and release from
the microtubules. However, if abnormal hyperphosphorylation occurs, tau dissociates
from the microtubules. Once released, the microtubules become unstable and the
aberrant tau mislocalizes from the axon to the somatodendric compartment, where it
aggregates. These aggregates are made of many pathological forms of tau including
oligomeric species, paired helical filaments, and neurofibrillary tangles, all of which have
associated toxicities. Tau pathology is a hallmark of Alzheimer’s disease, one of over 15
diseases known as tauopathies which present with tau pathology, all of which lack
effective treatments. Heat shock protein 90 kDa (Hsp90) is a major adenosine
triphosphate (ATP)-dependent regulator of non-native proteins, like misfolded tau.
Although Hsp90 is able to effectively refold and degrade many aberrant proteins, it has
been associated with preserving aberrant tau. In fact, inhibiting the Hsp90 ATPase
activity leads to the degradation of tau, which has been demonstrated in a number of
models with the use of various Hsp90 inhibitors. However, there are many side-effects
associated with the use of these inhibitors including toxicity and heat shock factor 1
(HSF1) activation. Although improvements on Hsp90 inhibitors are still in progress, this
study explores targeting Hsp90 through a slightly different mechanism, by targeting
viii

Hsp90 co-chaperones.

Hsp90 is involved in almost every pathway in each cell

throughout the body. Co-chaperone proteins assist Hsp90 in these various processes,
but are each only involved in a subset of the total Hsp90 interactome.

Therefore,

targeting Hsp90 co-chaperones could lead to improved efficacy, potency, and safety of
drugs designed toward Hsp90 for the treatment of tauopathies. We previously showed
one of these co-chaperones, FK506 binding protein 51 kDa (FKBP51), a
tetratricopeptide repeat (TPR) domain containing immunophilin, coordinates with Hsp90
to regulate tau metabolism. More specifically, we found that increases and decreases in
FKBP51 levels correlated with increases and decreases in tau levels, respectively.
FKBP51 knockout mice have been extensively studied and have shown no
negative phenotypes in these characterizations. In this study, we found that this mouse
model has decreased endogenous tau levels. Furthermore, this study demonstrates that
FKPB51 colocalizes with pathological tau in the AD brain, and synergizes with Hsp90 to
preserve tau from proteasomal degradation. Additionally, FKBP51 overexpression in
mouse model of tau pathology leads to the preservation of tau. We went on to
characterize this accumulated tau as being neurotoxic and oligomeric in nature, while
being low in silver positive, β-sheet structure. In the human brain, we found that
FKBP51 is strikingly increased with aging and even further in the AD brain. In support of
these findings, we also found age-associated decreased methylation in the FKBP5
gene, which encodes FKBP51. Moreover, we found that increasing levels of FKBP51
caused other co-chaperone to have reduced Hsp90 binding and led to tau preservation.
This supports a model where age-related increases in FKBP51 lead to the preservation
of misfolded tau species and ultimately disease.
ix

In order to model the high FKBP51 expression found in the aging brain, we
generated the first FKBP5 overexpressing mouse model, which is tet-regulatable. This
mouse, rTgFKBP5, was made by targeted, single insertion of the human FKBP5 gene
into the HIP11 locus of the mouse genome crossed with CamKIIα tTa mice. We have
now confirmed high FKBP51 levels in the forebrain and hippocampus of this mouse,
which will serve as a testing platform for FKBP51 regulating drugs.
Overall, this work exemplifies FKBP51 as an important regulator of tau
metabolism through Hsp90. With the absence of a negative phenotype in mice ablated
of FKBP51 and the development of this novel, FKBP51 overexpressing mouse model,
strategies designed to decrease FKPB51 levels or to disrupt the FKBP51/Hsp90
complex could be relevant for the treatment of tauopathies, like AD.

x

CHAPTER ONE:
RATIONALE FOR TARGETING HSP90 THROUGH CO-CHAPERONE PROTEINS
FOR THE TREATMENT OF ALZHEIMER’S DISEASE

1.1 Abstract
The microtubule stabilizing protein, tau, becomes hyperphosphorylated and
accumulates in neurological diseases, called tauopathies. The most common tauopathy
is Alzheimer’s disease (AD) which has no cure. Chaperone proteins in the cell, like heat
shock protein (Hsp) 90 kDa, work in large complexes to direct tau triage. Hsp90 does no
act on client proteins alone, but instead corporates with a wide variety of co-chaperone
proteins. Small molecule inhibitors of Hsp90 have been shown to successfully clear tau,
predominantly phospho-tau species, making Hsp90 inhibitors are a promising
therapeutic intervention for tauopathies, like AD. However with many off target effects,
due to the many functions of Hsp90 complexes, further development to increase
specificity, potency and permeability is needed. This chapter discusses the most current
developments in Hsp90 inhibitors including blood-brain barrier permeability and
decreased toxicity. Additionally, targeting Hsp90 through co-chaperone proteins with be
discussed, with an emphasis on developments in targeting FKBP51, an Hsp90 cochaperone, to increase specificity in targeting tau.
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1.2 Introduction
Molecular chaperones are a family of proteins involved in the regulation of other
protein in the cell1. Many of these chaperones are heat shock proteins (Hsp) which
regulate processes from the folding of nascent chain proteins, to the refolding and
degradation of misfolded proteins2. Hsp90 is a ubiquitous chaperone protein which
utilizes ATP to perform regulatory functions in almost every pathway in the cell3,4. Hsp90
is comprised of a nucleotide binding domain at the N-terminus, a client and cochaperone binding site in the middle domain, and a C-terminal dimerization domain5.
This highly conserved protein has two cytosolic and two organelle bound forms, all of
which work together to maintain cell homeostasis6. The inducible cytosolic Hsp90 is
known as Hsp90α and the inducible form is termed Hsp90β, however not much more is
known about the differences between these two forms. Even less studied are the
organelle-bound Hsp90s, which include the endoplasmic reticulum (ER) resident
glucose-regulated protein 94 (GRP94) and the mitochondrial associated tumor necrosis
factor receptor associated protein 1 (TRAP1)7. Thus, this chapter will focus on
therapeutics designed to target cytosolic Hsp90.
Although Hsp90 has been shown to properly refold aberrant proteins, it has been
shown to lead to the preservation of pathological tau. In fact, inhibiting the ATPase
domain of Hsp90 has been previously shown to be effecting at stimulating tau
degradation8,9. Tau normally functions to stabilize the microtubules, however in disease
state,

becomes

hyperphosphorylated

and

misaggregates

leading

to

neurodegeneration10. Aggregation of tau is a hallmark in Alzheimer’s disease (AD) and
2

other neurological diseases, called tauopathies11,12. Since Hsp90 actually facilitates
increases the accumulation of tau, and under certain conditions, Hsp90 can enhance
tau toxicity13. Thus, small molecule inhibitors of Hsp90 have been generated to
regulated tau biology. Since there the two terminal domains of Hsp90 both contain
ATPase activity, small molecule inhibitors have been made towards each end and
inhibit Hsp90 in different steps of protein refolding14. Furthermore, Hsp90 inhibitors
which bind to the N-terminus activate heat shock factor 1 (HSF1) which regulates the
expression of other chaperones such as Hsp70 and Hsp279 and inhibitors which bind to
the C-terminus do not activate HSF1. Hsp90 inhibition through either route is effective at
decreases tau levels15. There have been many advances in building small molecule
inhibitors toward the ATPase activity of Hsp90. This chapter will discuss these recent
improvements on both N-terminus specific and C-terminus specific inhibitors.
Cytosolic Hsp90 works as a large protein complex, with other chaperones and
co-chaperones to maintain homeostatic balance within the cell. While Hsp90 is a part of
complexes which have roles in the folding and degradation of many important clients in
a number of processes, Hsp90 co-chaperones play a more targeted role in these
cellular processes16. There are two classes of these proteins, those which bind to
Hsp90 via a tetratricopeptide (TPR) domain and those which do not contain this
domain7. The TPR containing co-chaperones that will be discussed include carboxyterminus of the Hsp70-interacting protein (HIP), Hsp70-Hsp90 organizing protein (HOP),
heat shock cognate 70-interacting protein (CHIP), and the TPR containing cochaperones which display peptidyl-prolyl isomerase (PPIase) activity, including: protein
phosphatase 5 (PP5), FKBP52, and FK506 binding protein 51kDa (FKBP51)17. While
3

other Hsp90 co-chaperones without a TPR domain are able to bind to Hsp90 including
Aha1 and cell division control 37kDa (Cdc37)18,19. This chapter will focus on the known
effects of Hsp90 modulation on tau, as depicted in Figure 1.1. Chemicals that are
known to modulate both Hsp90 and its co-chaperones will be discussed, with a
particular emphasis on the immunophilin FKBP51.

1.3 New developments in cytosolic Hsp90 inhibitors
Although, inhibitors have now been identified for each ATPase domain of Hsp90,
the first class to be really developed was those targeting the N-terminus, which has a
classical ATP domain14. In addition to inhibiting the ATPase activity of the N-terminus,
these inhibitors activate heat shock factor 1 (HSF1), which subsequently leads to the
elevation of Hsp27 and Hsp709. However, both N-terminal and C-terminal targeting
Hsp90 inhibitors are able to effectively decrease tau levels. This chapter will focus on
the recent advances in the identification and development of these inhibitors.
The first Hsp90 inhibitor to be identified was the antibiotic geldanamycin (GA)20.
GA treatment has been shown to preferentially reduce phosphorylated tau21, but had a
poor toxicity profile22. Moreover, disease-like states increase the binding of these
geldanamycin scaffold inhibitors to Hsp9023, which was shown to rapidly degrade tau in
a mouse model of tauopathy24. Improvements on this antibiotic were made to increase
the potency and reduce toxicity leading to the second generation of Hsp90 inhibitors.
These new inhibitors included the well-known and markedly less toxic analog, 17(allylamino)-17-demethoxygeldamycin (17-AAG). However, even with increased blood-
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brain barrier (BBB) permeability, this development was not able to increase the
bioavailability of these compounds.
The purine scaffold has generated many more N-terminal targeting Hsp90
inhibitors. One of these inhibitors, EC102, is BBB permeable and was shown to potently
reduce tau levels in a human tau mouse model9. The more newly developed, purine
based PU scaffold, including PU24FCl, includes compounds which are highly soluble in
water8. Studies have clearly shown these inhibitors to be effective towards the ATPase
activity of Hsp9025; however, studies looking at the effects on tau biology have not been
reported to date. Therefore, N-terminal Hsp90 ATPase inhibitors show promising results
in reducing tau levels, especially with increased BBB permeability. However, off-target
effects of these compounds still remain, including eliciting a strong heat shock
response26.
The C-terminal inhibitors, which do not activate HSF1, were originally based off
of the novobiocin scaffold27. KU-32 and A4 were developed from improvements on this
base scaffold22,28. While C-terminal inhibitors are available, not much information is
known about the regulation of tau biology from C-terminal Hsp90 inhibition. However,
recent work has shown this class of inhibitors could prove effective at regulating tau
degradation29.

1.4 Targeting Hsp90 co-chaperones increases specificity
Hsp90 triages non-native proteins by either refolding or targeting for degradation.
These roles are carried out through the help of a number of Hsp90 co-chaperones.
Some Hsp90 co-chaperones are associated with refolding client proteins, Aha1, Cdc37,
5

PP5, FKBP51, FKBP52, and HOP30-32; inversely, some co-chaperones are known to be
biased towards the degradation of client proteins like CHIP. Hsp90 co-chaperone
complexes have been shown to diversely modulate tau by our laboratory and
others10,13,33-36. The Sansalvamide A scaffold, which prevents the binding of cochaperone proteins to the C-terminus of Hsp90, is a promising set of compounds to
target Hsp90 co-chaperone interactions37. The McAline lab recently synthesized
derivatives which differentially regulate co-chaperone binding to Hsp9038. However, the
potency of these drugs towards tau reductions has not been determined. Derivatives
from this scaffold or other co-chaperone modulating drugs could allow for targeting of
Hsp90 through more potent, less off-target drugs4. Although many co-chaperones have
not been well studied in regards to tau, they could provide new directions for future
research.
Aha1 is a one of a kind co-chaperone which stimulates Hsp90 ATPase activity39.
Our lab previously showed that tau levels are decreased upon Aha1 knockdown18,
however, not much more is known in relation to tau biology. Additionally there are no
specific inhibitors are available for Aha1, but Aha1 may be a good target to design
therapeutics towards for effectively regulating tau through Hsp90.
Cdc37, studied most for its role in refolding kinases, was previously shown by our
lab to correlate with tau levels36. In words, this study showed that tau preservation was
increased upon Cdc37 overexpression and inversely, tau levels were depleted when
Cdc37 was knocked-down. There are two inhibitors of the Hsp90/Cdc37 complex
Celastrol40 and Withaferin A41,42. Studies using either of these drugs lead to decreases
in tau levels while activating HSF143,44. Since Hsp27 and Hsp70 were induced and both
6

regulate tau biology15, it is difficult to determine the direct effect of targeting Cdc37.
More experiments will need to be done to determine if the Cdc37/Hsp90 complex is a
good target in regulating tau.
Hop facilitates the transfer of clients between Hsp70 and Hsp90 through its three
TPR domains45. Previous work has shown that tau levels inversely correlate to Hop18.
Although, C9, an Hsp90/Hop specific inhibitor has been identified46, no studies have
been performed to determine the effects on tau biology.
Unlike the previous mentioned co-chaperones, there has been extensive studies
looking at the effects of the E3 ubiquitin ligase, CHIP, on stimulating tau degradation9,47.
A study using CHIP knockout mice revealed mice ablated for CHIP show higher tau
levels than wild-type littermates48. Therefore the development of drugs which stimulate
the expression of CHIP or increase its binding to Hsp90 may lead to reduced tau levels.

1.4.1 Hsp90 and PPIases
The importance of PPIase proteins regulating tau biology was first by Pin149.
This important family functions to isomerize cis-trans conformation of phosphoserine/threonine-proline motifs and regulate their phosphorylation

50

. Recently, work

from our lab and others has shown that other PPIases, such as FKBP51 and FKBP52
can also regulate tau metabolism13,35,51-53. Unlike Pin1, the PPIase proteins which will
be discussed function though binding to Hsp90, however similar to Pin1 they may be
effective at regulating tau metabolism.
One member of the protein phosphatase family, PP5, regulates the
phosphorylation of many important pathways54-59. We previously reported that knocking7

down PP5 led to decreased tau levels18. Additionally, PP5 was previously shown to
regulate tau phosphorylation60. Therefore, drugs which stimulate PP5 activity or lower
PP5 levels may prove to negatively regulate tau levels.
The Hsp90/FKBP52 complex has been well characterized for its role in the
regulation of steroid hormone complexes61. However, there is quite a bit is also known
about the regulation of tau biology by FKBP52. The Baulieu lab elegantly showed that
FKBP52 can directly bind to tau and preferentially bind to hyperphosphorylated,
pathogenic tau species52. Furthermore, this study showed that this interaction had a
functional effect on tau. That is when FKBP52 was bound to tau; tau was no longer able
to stabilize the microtubules. In a study from our lab, we found that FKBP52 knockdown
preferentially increased total tau, but not phospho-tau18. In a more recent study, the
Giustiniani et. al. found that FKBP52 interacted with tau to produce tau oligomers53,
similar to the results our lab found with FKBP51 and tau13.
Similar to FKBP52, FKBP51 is most well studied as a part of steroid hormone
complexes62. However, we have found that FKBP51 has a role in tau biology13,35. The
FKBP51 protein is comprised of two domains (FK1 and FK2) which are FKBP-like and
exhibit PPIase activity63, which allow for the direct binding of immunosuppressive drugs
like FK506, rapamycin, and cyclosporin64.

This FKBP-like domain, which is found

similarly in other immunophilins, makes identifying drugs which specificity bind to one
FKBP protein quite difficult. Furthermore, targeting the FKB-like domain would block the
binding of progesterone receptor and AKT (protein kinase B). Moreover, FKBP51
contains a TPR domain, which permits binding to glucocorticoid receptors (GR),
FKBP51, androgen receptors, and two pleckstrin homology domain and leucine-rich
8

repeat protein phosphatases (PHLPP1 and PHLPP2). Drugs designed towards this TPR
domain could be beneficial at preventing most of the association of FKBP51 with tau
through Hsp90. Furthermore, targeting this domain would prevent association of
FKBP51 with GR, which may lead to effective regulation of this steroid hormone, which
is known to have deleterious effects in AD and other psychiatric diseases65-67.
There is ubiquitous expression of the FKBP5 gene in most cell types68 and
tissues of the body69. FKBP51 is highly expressed in T-cells and neurons in the brain
and can localize to both the cytoplasm and nucleus of the cell. FKBP5 expression is
induced upon activation of the hypothalamic-pituitary adrenal (HPA) axis70. FKBP51 is
most well-known for the important role it plays in regulating GR transactivation.
FKBP51 is part of a short, negative feedback loop activated by GR which leads to
FKBP51 upregulation. This acts to slow the activity of GR by decreasing the affinity of
GR for glucocorticoids71.
Recent studies have linked numerous single nucleotide polymorphisms (SNPs) in
FKBP5 to increased risk for PTSD72, major depressive disorder (MDD)73, aggressive
behavior

74

, suicide

75

, immune dysfunction76, and psychosis

77

. These SNPs are

associated with increased FKBP5 expression. We recently showed increased
expression of FKBP51 in AD, but no SNP has been linked to this disease

13

. A SNP

which is fairly common among many of the psychiatric diseases, rs1360780, is the only
SNP to have a known functional effect on FKBP5, where the T risk allele allows for
stronger binding to the TATA box protein leading to a two-fold increase in FKBP51
protein78.
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Fujii et al. showed that a T risk allele for the common SNP rs1360780 was able
to regulate the expression of both FKBP5 and GR in humans exposed to a
dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test. Interestingly, the
regulation of FKBP5 and GR was age-dependent and mimicked what has been
measured in PTSD patients79. This correlates with what is seen in FKBP5-/- mice,
where a phenotype can be found only under conditions of stress or aging.
FKBP5 is located on the short arm of chromosome 6, which has many genes that
have identified polymorphisms associated with cancer80, rejections of transplantations81,
and autoimmune disease82. The FKBP5 SNP rs1360780 was shown to have significant
linkage disequilibrium with human leukocyte antigen (HLA)-DR6, a chromosome 6 gene
linked to inflammation and transplant outcome83. This ancestral haplotype was
associated with resistance to glucocorticoids. For a more comprehensive chapter on
SNPs found in FKBP5 and associated diseases see Zannas and Binder 201384.
In addition to brain-related diseases, targeting FKBP51 has also been of
therapeutic interest in pancreatic cancer. Decreasing FKBP51 levels with shRNA
suppressed tumor growth through dephosphorylation of AKT, an effect mediated by
PHLPP85. In a separate study, the genetic variant rs73748206 was found to have a
positive correlation with chemoresistance in pancreatic cancer86. AKT phosphorylation
is common to many cancers; targeting this pathway by decreasing FKBP5 expression or
FKBP51 levels would be of interest in many forms of cancer. In the interest of AD, AKT
activation also has been shown to contribute to tau phosphorylation likely through
PAR1/MARK2. Additionally, suppression of AKT leads to lower CHIP levels, which in
turn would increase tau levels, by decreasing tau degradation by the ubiquitin
10

proteasome system87. A detailed look at role FKBP51 plays in the regulation of tau by
AKT and CHIP has yet to been explored.
Multiple groups have been involved in characterizing mice ablated for FKBP51,
the FKBP5-/- mouse model. These studies have showed no detectible negative
phenotypes associated with knocking-out FKBP5188,89. Moreover, these studies
demonstrated that mice ablated for FKBP51 actually show less depressive-like
episodes than wild-type mice in behavior tests when they are stressed or aged. This
work exemplifies that targeting FKBP51 through therapeutics is likely to have few
negative side effects. Recent work from our lab showed that there is a clear increase in
FKBP5 expression with aging in the human brain13. This age-dependent increase is also
present in murine brain tissue35,89. The mechanism by which FKBP5 expression is
increased over time is partially due to demethylation of the FKBP5 gene. Demethylation
of the FKBP5 gene has been shown in chronic corticosterone treatment in mice90 and in
the human brain in psychiatric diseases like PTSD91. There are many genes which are
up regulated with age in the brain, many are a part of the inflammatory and stress
response systems, along with those regulating DNA repair and synaptic plasticity92.
However, our previous study showed that Hsp90 and other Hsp90 co-chaperones
STUB1 (CHIP) and FKBP4 (FKBP52) did not share a similar increase with age, like
FKBP513. This age related increase in FKBP5 expression correlates with age dependent
cognitive decline. Additionally, high FKBP5 expression in the brain is been linked to
decreased hippocampal volume. FKBP5 has also been shown in many studies to
increase NF-ĸB. The inhibition of this protein was recently shown to increase lifespan in
a Drosophila model93. Thus, decreasing FKBP51 levels may mimic the increased
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lifespan seen by the NF-ĸB inhibitor, pyrrolidine dithiocarbamate (PDTC) and, inversely,
increased levels may lead to accelerated aging13,91.
FKBP51 is well characterized for its immunosuppressive effects in T-cells
through suppression of calcineurin, a protein phosphatase, when bound to FK506 or
other immunosuppressive drugs64. However, drugs targeting this region of FKBP51 may
be capable of inducing similar immune suppressing effects, which could lead to
susceptibility to other unnecessary infections.

Alternatively, the TPR domain of

FKBP51, which facilitates the binding of Hsp90 and steroid hormones, could be used as
the target for rational drug design. It was found that inactivating the PPIase domain of
FKBP51 did not change the regulation of GR in a non-human primate model94; targeting
the TPR domain may be more effective at regulating this process. Lastly, protein
complexes, such as the FKBP51/Hsp90/GR complex or a combination of those
proteins, could be potential therapeutic targets. A GR reporter gene assay is
commercially available to assess changes in GR activity and can be used in the
screening of small molecules95.
Therefore, there is a lot known about FKBP51 biology, and there are many tools
available to aid in the design drugs which specifically target FKBP51. This includes
having a full crystal structure which has been solved63,96. However, with about 70%
share sequence homology with FKBP52 a specific drug will still be difficult to identify97.
Taken together, this shows that more work is needed to identify the domain of FKBP51
which is most important to target for its interactions with tau and GR. Moreover, this
work exemplifies the need to develop new therapeutics for targeting FKBP51.
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1.5 Conclusions
The major chaperone Hsp90 presents a desirable target for therapeutics to
regulate tau biology. This major chaperone is just that, a major regulator of many
processes throughout the cell and all throughout the body. Studies have clearly
demonstrated that inhibition of Hsp90 leads to the clearance of many tau species, but
this inhibition is linked to many off target effects. Some of these side effects are even
toxic, which is not very surprising for targeting an essential, ubiquitous protein. Recent
developments in Hsp90 inhibitors have increased specificity for homologues of Hsp90,
lower toxicity, and increased preference for pathological tau. This is hopeful for the
generation of viable Hsp90 therapeutics, but increased specificity for Hsp90 regulated
pathways may lead to more promising results. Co-chaperones of Hsp90 assist in more
specified pathways, but there are few drugs available which specifically regulate these
Hsp90 co-chaperone complexes. One of these co-chaperones, FKBP51, could be an
ideal target for tau altering therapeutics. Given the absence of a negative phenotype in
mice ablated for the FKBP5 gene, drugs designed to lower the levels of FKBP51 or the
Hsp90/FKBP51 complex could be able to alter tau levels with limited side effects.
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Figure 1.1. A schematic of the degradation of tau through Hsp90 modulation. The
metabolism of the microtubule associated protein tau can be modulated through Hsp90
regulation via Hsp90 co-chaperones and inhibitors. Tau becomes hyperphosphorylated
in disease and forms oligomers and tangles. Hsp90 inhibitors block the release of
clients, like tau, leading to proteasomal degradation, while Hsp90 co-chaperones have
differential effects on tau metabolism. Co-chaperones with TPR domains bind to the Cterminus of Hsp90, as do some Hsp90 inhibitors. However, the majority of Hsp90
inhibitors bind the N-terminal domain.
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CHAPTER TWO1:
ACCELERATED NEURODEGENERATION THROUGH CHAPERONE-MEDIATED
OLIGOMERIZATION OF TAU

2.1 Abstract
Aggregation of tau protein in the brain is associated with a class of
neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa
(FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that
prevents tau degradation. In this study, we have shown that tau levels are reduced
throughout the brains of FKBP5-/- mice. Recombinant FKBP51 and Hsp90 synergized
to block tau clearance through the proteasome, resulting in tau oligomerization.
Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51
preserved the species of tau that have been linked to Alzheimer's disease (AD)
pathogenesis, blocked amyloid formation, and decreased tangle load in the brain.
Alterations in tau turnover and aggregate structure corresponded with enhanced
neurotoxicity in mice. Our data support a model in which increased FKBP51 levels and
its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at
attenuating FKBP51 levels or its interaction with Hsp90 has the potential to be
therapeutically relevant for AD and other tauopathies.
____________________
1

Portions of this work were previously published (Blair LJ et al, 2013) and are used with
permission of the publisher.
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2.2 Introduction
Neurofibrillary tangles, hallmarks of a class of neurodegenerative diseases
termed tauopathies, are comprised of microtubule-associated tau protein aggregates
that persist in the brain even after neuron death11. In the most common tauopathy,
Alzheimer’s disease (AD), the presence of these tangles correlates with pathological
development and disease progression. However, levels of neuronal death in AD far
exceed what is expected based on the observed numbers of tau tangles98, suggesting
that a different mechanism is primarily responsible for neurodegeneration. One possible
explanation for this discrepancy is that soluble tau species not visible by standard
histological methods are the main cause of neurotoxicity in tauopathies99. In fact,
neurons may form tangles as a protective mechanism to sequester these more toxic
soluble intermediates and convert them into a less harmful form100,101. These soluble tau
species may also be able to spread from neuron to neuron in a fashion similar to prions,
further establishing their role in perpetuating pathogenicity102-104.
Mutations in MAPT, the gene encoding tau, can also lead to the production of
soluble tau conformers with pathogenic potential, leading to rarer tauopathies such as
progressive supranuclear palsy (PSP) and frontal temporal dementia with parkinsonism
linked to chromosome 17 (FTDP-17)105-107. Thus, identifying the mechanisms that
contribute to the production of soluble tau intermediates could be paramount for
developing therapeutic approaches to treat AD and other tauopathies.

Since tau

dysfunction is somehow precipitated from within the neuron, chaperones may play a
central role in preserving or even facilitating tau conformations that can lead to its
toxicity.
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Chaperone proteins, like major chaperone Heat shock protein 90 kDa (Hsp90),
play major roles in the triage of de novo and non-native protein species, such as
refolding or degrading misfolded tau4. Hsp90 works as part of a large protein complex
with co-chaperones which interact when bound to specific targets3.

We previously

found that one of these co-chaperones, FK506-binding protein 51 kDa (FKBP51), coded
by FKBP5, interacts with Hsp90 to preserve tau in the cell35 and that knock-down of
FKBP5 dramatically decreases tau levels.
FKBP51 is an immunophilin with peptidyl-prolyl isomerase activity, which also
has a tetratricopeptide (TPR) region which allows for direct binding to Hsp9064. We
sought to identify a major mechanism by which FKBP51 could work with Hsp90 to
prevent tau degradation. Our findings suggest that FKBP51 synergizes with Hsp90 to
preserve tau degradation by the 20S proteasome and maintains this tau in a toxic, low
β-sheet content, oligomeric state.

2.3 Materials and methods
2.3.1 Ethics statement
All studies were carried out following the guidelines set by the University of South
Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance with the
Association for Assessment and Accreditation of Laboratory Animal Care International
(AALAC) regulations.

17

2.3.2 Materials
Antibodies: pT231 (Anaspec), Tau V-20 (Santa Cruz Biotechnology), PHF1 (pS396/404;
gift from Dr. Peter Davies, The Feinstein Institute for Medical Research, Manhasset,
NY), CP13 (pS202/t205; gift from Dr. Peter Davies), Tau12 (N-Terminal 2-18; gift from
Dr. Lester Binder, Northwestern University, Chicago, IL), pT231 (Abcam), NeuN
(Millipore), Neurotrace (Invitrogen), H150 (Santa Cruz), GFP (Invitrogen), T22 (Dr.
Rakez Kayed, University of Texas Medical Branch, Galveston, TX), Hsp90 (BD
Biosciences), GAPDH (Meridian Life Science), FKBP51 (gift from Marc Cox), and
FKBP51 (Cell Signaling)
Viruses: Adeno-associated virus serotype (AAV) 9 FKBP5 (Dr. Todd Golde, University
of Florida, Gainesville, FL) and AAV9 EGFP (gift from Dr. Kevin Nash, University of
South Florida, Tampa, FL) were obtained for murine gene therapy studies.
Human Tissue: Human tissue was obtained from the University of California at Irvine
MIND Alzheimer’s disease Research Center (Irvine, California).

2.3.3 Western and dot blot analysis
Samples extracted from brain tissues were analyzed by Western blotting using
10% acrylamide gels43. Antibody dilutions were 1:1000 unless otherwise stated. All
secondary antibodies were used at 1:1000 (Southern Biotech). Blots were developed
using ECL (Pierce) on a LAS-4000 mini imager (GE Healthcare). For dot blots, proteins
were applied onto a wet nitrocellulose membrane, rinsed three times with phosphate
buffered saline, and dried by vacuum.

Once dry, membrane was blocked and
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developed as described above. For T22 dot blots with recombinant protein, 50ng of tau
was the minimum required for T22 detection.

2.3.4 Protein purification
Production and purification of recombinant proteins was based on protocols
described previously108. Briefly, WT 0N4R tau, FKBP51, Hsp90α was cloned into pET28
vectors containing an N-terminal polyhistidine tag. Proteins were expressed in E. coli,
and purified via Ni–NTA–Sepharose chromatography. With the exception of FKBP51, all
proteins were subsequently purified by size-exclusion chromatography with a Superdex
200 column. Verification by Coomassie Brilliant Blue-stained SDS polyacrylamide gels
was used to determine the purity of all proteins.

2.3.5 20S proteasome assay
6μg 20S proteasome (ENZO Life Sciences) was incubated with 1μM ON4R-Tau
(final volume 10μl) for the 5 minutes in reaction buffer at 37°C (50mM Tris pH 7.5,
50mM KCl, and 0.2mM DTT). FKBP51 and HSP90 (concentrations are indicated in
figure) were added in lanes indicated. FKBP51 and HSP90 were pre-incubated with tau
for 5 minutes prior to addition of 20S proteasome. Reactions were stopped by adding
laemmli buffer and boiling 4 minutes. Samples were then resolved on a 15% SDSPAGE gel and analyzed by Western blot. To determine if FKBP51 inhibited 20S activity
100μg Suc-LLVY-AMC was incubated with 6μg of 20S proteasome for 5 minutes at
37°C.

Readings were then taken with an excitation wavelength of 380nm and an

emission wavelength of 460nm.
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2.3.6 Circular dichroism spectroscopy
Far- UV circular dichroism (CD) measurements were performed on a JASCO J815 spectropolarimeter. The proteins (WT 0N4R tau, FKBP51, Hsp90) were dialyzed
overnight in 10mM sodium phosphate buffer, pH 7.5 and the concentration was
determined using a commercially available BCA kit (Pierce). The proteins were mixed
prior to transfer to a 1mm quartz cuvette and measured at 25oC. Each spectrum is the
average of 3 scans from 190-260nm at a rate of 50nm/min. Control curves from buffer
alone were subtracted for each experiment. The calculated spectrums were determined
by simple addition of the indicated individual protein spectrums.
Tau aggregation measured by dynamic light scattering and Thioflavin T fluorescence
All proteins were dialyzed overnight into buffer containing 20 mM Tris-HCl and
100 mM NaCl at pH 7.4. The concentrations of purified tau, FKBP51, Hsp90α were
determined using the UV extinction coefficients at 280nm of 0.155, 0.788, 0.700, and
0.694 M-1 cm-1 respectively 109.
Recombinant P301L tau (300 μM) was combined with FKBP51 and/or Hsp90 at a
stoichiometric ratio of 50 parts tau to 1 part FKBP51 and/or 1 part Hsp90. All proteins
were filtered through a 0.2 μm syringe filter (Anotop) and a 100 kDa molecular cutoff
filter (Nanosep). Hsp90 and FKBP51 required an additional filtration through a 0.02 μm
filter (Anotop). Heparin sodium salt (MP Biomedicals LLC cat#194114) was filtered
through a 0.2 μm and 0.02 μm syringe filter and added at 75 µM to initiate aggregation.
Samples were placed in a Greiner Bio-One 384 well glass-bottom plate (cat# 781892),
incubated at 37°C, and aggregation kinetics in each well were monitored for 3 min every
2 hours using a Wyatt DynaPro DLS Plate Reader Plus. The low molar ratios of
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FKBP51 or Hsp90 to tau ensured that the DLS correlation function was dominated by
the scattering of tau. Mean aggregate radius were plotted as a function of time using
Igor Pro and fitted using the sigmoidal curve described by the following equation:
𝑅ℎ = 𝑅ℎ(𝑚𝑖𝑛) +

𝑅ℎ(𝑚𝑎𝑥)
1 + exp([𝑡ℎ𝑎𝑙𝑓 − 𝑡]⁄𝜏)

where t half is the time in days to reach half the maximum aggregate radius and the
apparent rate constant, k app is equal to 1/ 𝜏. Thus, a larger apparent rate constant
indicates a faster increase in aggregation110.

After incubation at 37oC for 6 days, Thioflavin T (ThT) fluorescence was
measured by removing the sample and diluting 30 fold into 10 μM ThT. The maximum
fluorescence intensity was measured at 485 nm with an excitation of 445 nm using a
FluoroMax-4 Spectrofluorometer (Horiba Jobin Yvon, Edison, NJ). Data from 3 dilutions
of each sample was averaged and normalized to a tau only control that was set at
100%.

2.3.7 AFM characterization of tau/Hsp90/FKBP51 aggregate morphology
Samples from the day 6 time point of the DLS measurements were diluted 1:10
in polymerization buffer, deposited onto freshly cleaved mica for 15 min, rinsed with
deionized water, and dried with dry nitrogen. Mounted samples were imaged in air with
an MFP-3D atomic-force microscope (Asylum Research) using PPP-FMR silicon tips
(Nanosensor) with a nominal tip radii of 7 nm. The cantilever was driven at 60–70 kHz in
alternating current mode at a scan rate of 0.5 Hz. Images were acquired at 1024x1024
pixel resolution.
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2.3.8 Cell culture and transfection
N2A cells were cultured in Opti-Mem plus media supplemented with 10% FBS and 1%
Penicillin-Streptomycin (Invitrogen). Primary neurons were harvested from P0 pups as
previously described (74). Briefly, newborn pups were immersed in 70% EtOH and
rapidly decapitated. Intact brains were removed and stored in dissociation buffer
containing HBSS supplemented with 1% sodium pyruvate, 0.1% glucose, and 10mM
HEPES (pH 7.3). Following removal of the meninges, brains were cut into small pieces
with a razor blade. Neurons were trypsinized and suspended in a single cell solution in
MEM media supplemented with 10% FBS, 0.45% glucose, 1% 100mM sodium
pyruvate, 1% 200 mM glutamax, and 1% Penicillin/Streptomycin. Cells were plated on a
96 well plate and grown for two weeks in Neurobasal media supplemented with 1% B27, 1% 200mM glutamax, and 1% Penicillin/streptomycin.

2.3.9 MTS assay
Primary neurons in 96 well plates were transduced for 14 days. N2A cells were plated in
96 well plates and transfected for 48 hours. At the end of the experiments MTS assays
(Promega) were performed. Replicate wells of no less than 8 replicates for each
treatment were analyzed.

2.3.10 Animals
The FKBP5 -/- colony was bred and genotyped as previously described89. The
rTg4510 colony was bred and genotyped as previously described101. Four month old
rTg4510 (n=5) and wild-type littermates (n=5) were stereotaxically injected bilaterally
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into the hippocampus at X= ±2.7 Y= -2.7 Z= +3.0. Each injection delivered 2 μL of
adeno-associated viral particles serotype 9 tagged with either green fluorescent protein
(GFP) or FKBP51. After 2 months of expression, mice were perfused with 0.9% saline.
Brains were immediately fixed with 4% paraformaldehyde overnight. Following sucrose
gradients up to 30%, tissue was sectioned using a sliding microtome into 0.2% sodium
azide in PBS. Sections for general histochemical staining were sectioned at 25 μm.
Additionally, 50 μm sections were taken for stereology.

2.3.11 Immunohistochemistry
Free floating staining was performed as previously described111. Briefly, sections
were incubated in PBS supplemented with 10% methanol/3% H 2 0 2 to block
endogenous peroxidases. Following PBS washes, tissue was permeabilized by 0.2%
Triton X-100 with 1.83% lysine and 4% serum in PBS, after 30 minutes, tissue was
incubated at room temperature in primary antibody. Tissue was incubated overnight
with either anti-pT231 tau (1:300), anti-FKBP51 (1:1000), or T22 (1:700). Following
three washes, biotinylated goat anti-rabbit (Southern Biotech) secondary (1:10000) was
added for 2 hours. Prior to peroxidase development, an ABC kit (Vectastain) was used
to

increase

visibility.

Following

washes,

tissue

was

incubated

with

0.05%

diaminobenzidine plus 0.5% nickel and developed with 0.03% H 2 0 2 . Sections mounted,
allowed to dry overnight and dehydrated in alcohol gradients. Slides were coverslipped
with DPX following clearing by Histoclear. Sections stained with cresyl violet (nissl) were
incubated with 0.05% cresyl violet briefly and quickly destained with 0.3% acetic acid in
water prior to dehydration. One series of sections was stained by immunofluoresence.
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This tissue was permeabilized as described above and incubated overnight with antiTau V-20 (1:50), anti-PHF1 (1:1000), anti-biotinylated NeuN (1:100), and anti-FKBP51
(1:300) or anti-GFP (1:300) respective to the injected virus. Following washes, sections
were incubated for 2 hours with goat anti-rabbit (1:3000), donkey anti-goat (1:1000),
and streptavidin (1:1000) AlexaFluor tagged secondary antibodies. Sections stained
with Neurotrace (1:25) (Invitrogen) were incubated following secondary for 20 minutes.
Human tissue was incubated in 0.1% Sudan Black B in 70% EtOH (Sigma) to
reduce auto-fluorescence for 20 minutes and then washed three times with 0.2% Tween
in PBS following fluorescent secondary. Tissue was mounted after three washes and
coverslipped with ProLong Gold antifade (Invitrogen) reagent. Gallyas silver stain was
performed as previously described for non-paraffin imbedded tissue112.
Sections stained for stereology were blocked and permeabilized as described
above and incubated overnight with biotinylated NeuN (1:3000) at room temperature.
Following washes, ABC conjugation, and peroxidase development tissue was mounted
on glass slides and dried overnight. A cresyl violet counterstain was applied to the
slides as described before coverslipping.

2.3.12 Microscopy
A slide scanning microscope (Mirax) was used to image all brightfield stained
tissue. Fluorescent microscopy was performed using a Leica TCS SP2 laser scanning
confocal microscope. Fields of view were selected in the hippocampus based on the
spread of the virus. Using a 63x/1.40-0.60 PLAN APO Oil objective, a minimum of 15 1
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μm Z-stacked images was collected from sections taken from each animal with Argon
and HeNe lasers.

2.3.13 Imaging analysis
Bright field analysis was performed using NearCYTE whole slide image analysis.
We used this program to outline regions of interest from the entire slide. Thresholds
were then manually set until all of the positive cells, as determined by the analyzer,
were selected while as little non-specific areas were selected as possible. Using the
batch process option, each stained group was automatically calculated for the Area
Ratio of positive cells within the determined regions of interest.
Fluorescent image analysis was performed using ImageJ as previously described
with minor modifications113. Briefly, images were opened and channels separated
(Red=Tau,

Green=FKBP51,

and

Blue=NeuN)

using

the

Bio-Formats

plug-in.

Background was subtracted from the Green and Red channels using the Gaussian Blur
tool (Radius = 50um) of the image and subtracting this new image from the original
image. Both the Green and Red channels were despeckled and a binary mask was
made of the Blue channel. Using the image calculator, we created a new image that
represented all neurons (Blue) and also FKBP51/GFP expressing (Green). Next, using
Analyze>Set measurements: we redirected this new image of only infected neurons to
the red (tau) channel. Individual cells were accounted for by using Analyze> Analyze
Particles and a radius of 50 to infinity. We then used the mean of the area and the
intensity density to determine the amount of tau (red) in those cells.
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To calculate the effect of the virus on all surrounding neurons, the same images
were used. We cleaned up the red channel by using background subtraction and
despeckling the images. A mask was made of all the neurons shown by the blue
channel. This mask was redirected to the red channel and the particles were analyzed
(100-infinity) to measure the area fraction of the red within the blue. This would tell us
how much tau was in each neuron in images taken that had virus expression in at least
one cell. Comparisons were made of the total area fraction between the FKBP51 and
GFP injected.

2.3.14 Stereology
Neurons were defined by NeuN and cresyl violet staining, those positive for both
were counted in the CA3. Using a computerized stereological system, connected to an
Leica DM4000B microscope with a Prior motorized stage, the area was outlined using
distinct landmarks in the brain using 4x magnification114,115. Neurons were counted in
this region by randomly designated areas in the computer generated grid using a 100x
oil immersion lens. Neurons, as defined by NeuN and nissl staining, were counted
when they were randomly located within the three-dimensional dissectors or touching
the inclusion lines.

The top and bottom 1 μM of tissue was excluded. The tissue

thickness was determined to be 10.48 ± .028 μM for all sections analyzed.

2.3.15 Statistics
To compare 2 groups, a student’s t-test was used. Groups larger than 2 were
evaluated using a 1-way ANOVA test. P values below 0.05 were considered significant.
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2.4 Results
2.4.1 FKBP51 depletion reduces tau levels in brain
Previous work showed that FKBP51 depletion reduced tau levels in cell models
of tauopathy35. However, it was not clear whether this was relevant in vivo. To address
this issue, brain tissue from FKBP5 knockout mice was collected and subjected to both
immunohistochemical and biochemical analyses. Mice were generated as previously
described89,116. Staining of FKBP5 -/- revealed a significant reduction in tau levels
throughout the brain (Figure 2.1, A-C). Similarly, Western blot analyses of brain
homogenates showed a similar reductions in several tau epitopes, including a
significant reduction in total tau (as assessed with the Tau 12 [amino acids 2-18] and
H150 [tau N terminus] antibodies) and phosphorylated tau (as assessed with the CP13
[pS202] and pT231 [PHF6] tau antibodies) (Figure 2.1, D-E). We then performed
fluorescent analyses to confirm that FKBP51 and tau were co-localized in neurons in
human brain. Immunostaining with FKBP51 antibody and PHF1 (pS396/S404 tau)
antibody that stains human AD brain well, combined with a neuronal marker showed colocalization of neuronal tau pathology and FKBP51 in AD cortex (Figure 2.2).

2.4.2 FKBP51 works with Hsp90 to synergistically block the 20S proteasome from
degrading tau
Previously we reported that FKBP51 coordinated with Hsp90 to promote the
accumulation of non-ubiquitinated tau in the presence of a proteasome inhibitor35. This
suggested that FKBP51 may be playing a role in ubiquitin-independent tau degradation
via the 20S proteasome, a process shown to be a major route of tau clearance117,118.
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The 20S proteasome serves as the catalytic core for the 26S proteasome119, and 20S
proteasomes can be about 3-4 times more abundant in cells than 26S proteasomes120.
In addition, FKBP51 was previously found to slow the degradation of tau by
chymotrypsin, the major protease of the 20S proteasome35. To determine unequivocally
whether the FKBP51/Hsp90 complex could alter the kinetics of clearing tau by the 20S
proteasome, we used a reconstituted in vitro assay as previously described117. Indeed,
tau was rapidly degraded by the 20S proteasome but this was partially blocked by
FKBP51 alone (Figure 2.3A). When Hsp90 and FKBP51 were combined, tau
degradation by 20S proteasome was completely blocked (Figure 2.3, B-C), whereas
Hsp90 alone had effects on tau similar to that of FKBP51 alone. The effects of FKBP51
and Hsp90 together were significantly greater than the additive effects of each
individually, suggesting true synergy (Figure 2.3D). Changes in degradation were not
attributed to non-specific alteration of the 20S proteasome, as the 20S reporter
substrate was not affected by the addition of FKBP51 (Figure 2.3E). Thus, FKBP51 and
Hsp90 synergized to prevent 20S proteasome-mediated tau clearance, implicating that
this chaperone complex not only is involved in tau turnover, but also suggests a novel
mechanism for FKBP51 in regulating intracellular 20S proteasome substrates.

2.4.3 FKBP51 coordinates with Hsp90 to produce non-amyloid, ThioflavinT-negative tau
oligomers
The synergistic effects of Hsp90 and FKBP51 directly on tau proteasomal
degradation suggested that these two chaperones somehow worked together to
regulate tau conformation and possibly its aggregation kinetics. To get a general idea
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about how FKBP51 and Hsp90 regulated tau structure, circular dichroism (CD) analyses
were performed with tau in combination with FKBP51, Hsp90 or both proteins together.
As previously shown, tau is an intrinsically disordered protein, and its CD spectra has a
minima at 200nm121. Indeed, the tau produced in our lab reproduced these results,
showing a spectrum from 190 to 260nm, typical for a highly disordered protein such as
tau (Figure 2.4A).

The secondary structures of FKBP51 and Hsp90 were also

determined by CD. Consistent with previous reports, FKBP51 and Hsp90 showed
substantial ordered secondary structure122,123. The PONDR-FIT algorithm, one of the
most accurate disorder predictors
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confirmed the CD data, indicating that tau is

almost completely disordered while FKBP51 and Hsp90 are largely ordered (Figure
2.5). Next, CD spectra were collected for tau in the presence of FKBP51 alone, Hsp90
alone, or both chaperones combined (Figure 2.4B). The dashed lines in Fig 2.4B show
the predicted spectra of these protein mixtures if no structural change were to occur.
These calculated spectral plots were obtained by summing the spectra from each of the
individual measurements taken for tau, FKBP51, or Hsp90; however, the observed CD
spectra (Figure 2.4B, shown as solid lines) were in contrast to the calculated spectra,
suggesting that structural changes were occurring when these proteins were combined.
While FKBP51 alone (3:10 ratio of FKBP51 to tau) had no effect on the secondary
structure of tau (Figure 2.4B), Hsp90 (2:10 ratio of Hsp90 to tau) did alter tau structure.
Interestingly, when FKBP51, tau, and Hsp90 were incubated together at a respective
3:10:2 ratio, tau showed a unique structural change unlike incubation with Hsp90 or
FKBP51 alone, suggesting that FKBP51 only affected tau structure when Hsp90 was
present.
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Since altering the structure of aggregation-prone proteins is known to contribute
to their pathogenic assembly into fibrillar structures125-128, we speculated that Hsp90
alone and Hsp90 with FKBP51 could alter tau fibril assembly.

We used dynamic light

scattering (DLS) to assess how the Hsp90/FKBP51 complex was regulating the kinetics
of global tau aggregation113.

For these studies, tau aggregation was induced with

heparin sulfate in the presence of either Hsp90 or FKBP51 alone, and in the presence
of Hsp90 and FKBP51 together. A 50:1 tau:chaperone ratio was used to minimize any
contributions of the chaperones themselves to the signal produced. Tau combined with
these Hsp90/FKBP51 mixtures was allowed to polymerize over a period of 6 days and
particle size distributions were determined with DLS throughout the duration of the
experiment. Similar to the results using CD spectroscopy, FKBP51 alone did little to
impact tau aggregation kinetics; both tau alone and tau with FKBP51 reached the halfmaximal size by 2.3 ± 0.3 days (Figure 2.6A). The rate of aggregation was also
unaffected (k app = 1.7 ± 0.3 days -1). Hsp90 alone actually accelerated tau aggregation
(time for half-maximal size, t half = 1.5 days ± 0.0; apparent rate, k app = 3.3 ± 0.0 days -1)
consistent with previous findings
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. Surprisingly, though, FKBP51 was able to slow the

Hsp90-induced tau aggregation (time for half-max size, t half = 2.1 ± 0.1 days; apparent
rate, k app = 2.0 ± 0.5 days

-1

)(Figure 2.6B), further supporting our hypothesis that

FKBP51 uses Hsp90 to regulate tau biology and specifically promote its pathogenesis.
Incubating these tau aggregates with Thioflavin T, a dye that specifically recognizes βpleated sheet amyloid structure, showed that Hsp90 promoted tau β-sheet aggregates,
but FKBP51 prevented this (Figure 2.6B). Therefore, FKBP51 prevents tau from
adopting β-sheet structure in the presence of Hsp90, promoting the production of
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amorphous tau aggregates. These results were confirmed using atomic force
microscopy (AFM) (Figure 2.6C). To determine whether recombinant tau was indeed
forming oligomeric structures, tau was incubated with FKBP51 or Hsp90 alone or with
FKBP51 and Hsp90 together with Heparin as described for the DLS experiment. The
mixtures of these proteins were then analyzed by dot blot with the anti-tau oligomer
specific antibody, T2299. Indeed, T22 positive tau was only observed in the presence of
FKBP51. The production of this oligomeric species was enhanced, even though total
tau levels were the same, when FKBP51 and Hsp90 were incubated together with tau
(Figure 2.6D). Hsp90 alone produced no T22 immuno-reactivity. In this way, FKBP51
causes Hsp90 to alter its structural influence on tau, leading to the formation of nonamyloid tau aggregates and oligomeric tau species, which have both been implicated as
the primary toxic tau species that facilitate neurodegeneration100,101,130,131. Based on
these findings, we speculated that FKBP51 over-expression in the brain may drive tau
toxicity. Therefore, we sought to evaluate the effects of FKBP51 in vivo.

2.4.4 In vivo, FKBP51 overexpression preserves tau species, including oligomers
The hippocampi (HPC) of a cohort of 4-month-old rTg4510 transgenic mice,
which express human P301L mutant human tau, were injected bilaterally with AAV9
particles expressing either FKBP51 (n=5) or GFP (n=5).

These mice have abundant

Hsp90 levels and low basal FKBP51 levels at 6 months of age, and they are the best
model to recapitulate human tau pathobiology101,111,130,132,133. Therefore, 2 months
following these injections, 6 month-old mice were harvested and examined histologically
as previously described111. FKBP51 expression was observed in the hippocampus;
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however the AAV did not transduce all neurons (Figure 2.7A).

Due to this typical

limitation of AAV use, a fluorescent masking technique previously developed by our lab
was utilized to evaluate the levels of tau in neurons expressing the AAV product, in this
case FKBP51 or GFP113. Triple immunofluorescent staining of sections for FKBP51,
total tau, and the neuronal marker NeuN revealed that the amount of tau found within
FKBP51-positive neurons was significantly increased compared to tau levels in neurons
overexpressing GFP (Figure 2.7, B-C). In fact upon further analysis of the site
surrounding the injection site, the levels of phosphorylated tau throughout the CA3
region were significantly higher in mice injected with FKBP51 compared to those
injected with GFP (Figure 2.8, A-B). Based on our in vitro results, tissue was then
stained with oligomeric tau antibody T2299. T22 tau was significantly increased in the
CA3 of FKBP51 injected mice, compared to GFP injected littermates (Figure 2.8, C-D),
indicating that FKBP51 was preserving tau in an oligomeric state. To further confirm the
accumulation of tau by FKBP51 in vivo, homogenized tissue from FKBP51 or GFP
AAV9 injected mice was analyzed by Western blot and dot blot (Figure 2.9A). Both
phospho-tau (pT231) and total tau (H150) were significantly preserved in mice injected
with FKBP51 AAV9 particles compared to GFP AAV9 injected littermates. In addition,
T22 oligomeric tau was significantly preserved in mice overexpressing FKBP51 (Figure
2.9B).

2.4.5 FKBP51 prevents tangle formation, but enhances tau neurotoxicity
Our in vitro data suggested that FKBP51 also prevented amyloid formation. The
rTg4510 mouse is one of the only transgenic models to produce Gallyas-silver positive
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tangles that are a traditional pathological hallmark for AD and other tauopathies111.
Gallyas silver stains the same structure as ThT134, but Gallyas lacks the fluorescent
properties of ThT. Thus, the previous characterization of Gallyas silver in this model
combined with its lack of fluorescence in the GFP spectrum made it the ideal stain to
assess ß-sheet structure in these studies. Silver positive tau was significantly reduced
in the CA3 region of mice injected with FKBP51 AAV compared to those injected with
GFP AAV (Figure 2.10, A-B). Thus, FKBP51 over-expression in neurons promoted the
accumulation of non-amyloid oligomeric tau species, similar to what was observed in
vitro.
The toxicity of these T22-positive/silver-negative tau species produced by
FKBP51 over-expression were then directly evaluated using unbiased stereology.
Indeed, in rTg4510 mice expressing FKBP51, there was a significant decrease in the
number of neurons in the CA3 hippocampal region compared to mice injected with GFP
AAV (Figure 2.11, A-B). This neuron loss did not significantly alter CA3 volume (Figure
2.11C).

Since this was the first time FKBP51 and tau have been shown to be

neurotoxic, we performed in vitro experiments to confirm this result. Primary neurons
from tau expressing pups were transduced with FKBP51 AAV9 particles and allowed to
express for 14 days. On the 14th day, an MTS assay was performed to measure toxicity.
Significant toxicity was found in tau expressing neurons transduced with FKBP51 AAV9
compared to GFP AAV9 transduced controls (Figure 2.12A). Additionally, Neuro2A
cells, a mouse neuroblastoma line, were transfected with tau, FKBP51, or the
combination for 48 hours. MTS assays performed at the end of the 48 hours revealed
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significant cell toxicity in the neuronal line, but only in the cells transfected with tau and
FKBP51 together (Figure 2.12B).

2.5 Discussion
We have found that a chaperone, FKBP51, can work with Hsp90 to produce
oligomeric tau in the brain, facilitating its neurotoxicity. FKBP51 over-expression
enhanced neuronal loss in the rTg4510 tau transgenic mouse model, suggesting that
FKBP51 coordinates with Hsp90 to prevent tau clearance and facilitate its toxicity. This
provides further evidence that other forms of tau, besides those that are pathologically
visible in post-mortem tissue like tangles, are highly neurotoxic101,130,135,136. Thus factors
that facilitate FKBP51 expression could promote an environment in the aging brain that
supports tau pathogenesis.
At the molecular level, these studies show that FKBP51 can prevent tau
clearance through the 20S proteasome without directly impairing 20S proteasomal
activity. This is one of the few examples where chaperones can coordinately interact
with a substrate, in this case tau, to block its degradation. This type of control of tau
degradation may be unique to tau because of its high level of disorder137. Since the 20S
proteasome typically proteolyzes unfolded proteins120, it is possible that FKBP51 and
Hsp90 bind tau, giving it more order and preventing its indiscriminate degradation
through the 20S proteasome. But this appears to come at a price: FKBP51 and Hsp90
also promote a structure for tau that produces toxicity, supporting the idea of the need
for balance in the proteostasis network for healthy neuronal aging and function138. When
chaperone levels are too high or too low, some substrates that are particularly difficult to
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handle can begin to accumulate and cause disease. These substrates can then have
detrimental consequences to the proteostasis system and general cellular health139-142.
Perhaps the most intriguing result from these studies is the discovery that a
chaperone can mediate the formation of tau oligomers. These data also show that
subverting

amyloid

formation

with

chaperones

could

produce

a

deleterious

consequence. Recent work has begun to question the role of amyloids in AD

143

. While

amyloid pathology (tangles, plaques, Lewy bodies, etc) is the hallmark of many
neurodegenerative diseases, these types of pathologies do not correlate well with
neuronal loss or dysfunction in animal models of disease. For example, in the rTg4510
tau transgenic mice, neurons with tau tangle structures are longer lived100,144. This same
model displays cognitive recovery when tau is suppressed, despite continued tangle
formation101,131. Moreover, strategies that deplete soluble intermediate tau species
without impacting tangle pathology have been very successful at improving cognitive
impairment and neuronal loss in transgenic tau models101,131,145. The current evidence
suggests that sequestration of misfolded or abnormally folded proteins into amyloid βsheet structures may be more beneficial to neurons than allowing these intermediates to
traverse the intracellular milieu146-148. FKBP51 not only interferes with tau degradation
and promotes tau oligomer formation, but it also impairs its ability to be sequestered into
less toxic tangles, facilitating tau toxicity. This is why strategies aimed at depleting
FKBP51 or inhibiting its association with tau or Hsp90 may be highly effective for taubased therapeutics.
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Figure 2.1. Tau expression is decreased in the FKBP5-/- mice. Representative
images of brain tissue from (A) wildtype and (B) Fkbp5 -/- mice stained for pT231 tau
and corresponding sections without primary. Scale bar: 2000 μm. (C) Quantification of
pT231 stain. *p=0.0097 (D) Representative Western blot of brain homogenates from
Fkbp5-/- mice probed for CP13 (pS202/pT205), Tau12 (total tau), pT231 tau, H150
(total tau), and GAPDH. (E) Quantification of duplicate Western blots (±SEM). *p<0.05
for CP13, Tau 12 (total tau), and H150 (total tau) ***p<0.001 for pT231.
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Figure 2.2. Tau associates with FKBP51 in the AD brain. (A) Fluorescent micrograph
of human cortex stained with FKBP51, PHF1 (pS396/pS404), and Neurotrace (neuronal
nuclei) antibodies (Original magnification, x60). Scale bar: 50μm.
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Figure 2.3. FKBP51 and Hsp90 synergistically prevent tau degradation by the 20S
proteasome. (A) Tau was incubated alone, with 20S proteasome, or with FKBP51 and
20S proteasome for 5 minutes. (B) Tau was incubated alone, with 20S proteasome, with
FKBP51, and with Hsp90 with or without FKBP51 for 5 minutes. (C) Relative tau levels
(± SEM) in each sample using 1 μM Hsp90. **P < 0.01, ***P < 0.001. (D) Tau levels (±
SEM) following incubation with FKBP51 and Hsp90 in the presence of the 20S
proteasome (green). Calculated tau levels (blue) from the addition of the results of tau
preserved following incubation with Hsp90 and with the tau preserved following
incubation with FKBP51 in the presence of the 20S proteasome. *P < 0.05. (E) FKBP51
was incubated with 100 μg Suc-LLVY-AMC and 20S proteasome for 5 minutes. OD
readings (± SEM) were taken at 460 nm.
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Figure 2.4. FKBP51 and Hsp90 alter the secondary structure of tau. (A) CD spectra
of tau, FKBP51, and Hsp90 recombinant protein. CD spectra were obtained at protein
concentrations of 10 μM tau, 2 μM FKBP51, and 3 μM Hsp90 in 10 mM sodium
phosphate buffer (pH 7.5) at room temperature. (B) CD spectra readout of tau incubated
with FKBP51, Hsp90, or both (solid lines). Calculated (calc) CD spectra (dashed lines)
from the addition of each protein’s spectra shows what the readout would display if
there were not protein interactions.
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Figure 2.5. Evaluation of intrinsic disorder propensity of human tau protein. Tau
(A), FKBP51 (B), and Hsp90 (C) by disorder predictor PONDR-FIT. The light pink, cyan
and yellow shadows around the corresponding PONDR-FIT curves show the statistical
error of PONDR-FIT predictions.
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Figure 2.6. FKBP51 and Hsp90 combine to produce oligomeric tau structures.
Measurements of tau filament formation were monitored daily for 6 days, with a reading
taken at least every 16 hours. (A) Tau fibril assembly was measured (± SEM) using DLS
in the presence of FKBP51, Hsp90, and both combined. DLS measurements of tau
filament formation were monitored daily for 6 days, with a reading taken at least every
16 hours. (B) Tau was stained with Thioflavin T (ThT) to show β-pleated sheet
aggregation after 6 days of incubation alone or with FKBP51, Hsp90, or both combined
(± SEM). ***P < 0.0001. (C) Atomic force microscopy images of tau multimers. The
product of the DLS was imaged using atomic force microscopy for conformation. Both
height (black) and amplitude (gray) images are shown. Scale bar: 0.5 μm. (D)
Recombinant proteins were applied to a dot blot after 6 days, with heparin incubation at
a ratio of 35 parts tau to 1 part chaperone combination. This was probed with T22 and
H150 (total tau) antibodies.
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Figure 2.7. FKBP51 overexpression by viral vector in rTg4510 mice preserves tau.
(A) GFP or FKBP51 was overexpressed in the HPC of rTg4510 mice using an AAV9
vector. Scale bar: 2,000 μm; 50 μm (inset). Original magnification, ×63 (inset). B) Total
tau (± SEM) was measured using ImageJ in neurons expressing FKBP51 or GFP. At
least 15 images were taken per animal. ***P < 0.0001. (C) Representative images
FKBP51- and GFP-expressing neurons (arrows) (original magnification, ×63) using
antibodies toward GFP (green), FKBP51 (green), total Tau (red), and NeuN (blue).
Scale bar: 50 μm.
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Figure 2.8. FKBP51 overexpression preserves phospho- and oligomeric tau
species. (A) Tissue from injected mice was stained for pT231 tau. pT231-positive area
(± SEM) was measured per CA3. *P = 0.0463. (B) Representative sections are shown.
Scale bar: 2,000 μm; 200 μm (inset). Original magnification, ×10 (inset). (E) T22
oligomeric tau (± SEM) was measured in the CA3 region of FKBP51- and GFPoverexpressing mice. *P = 0.0176. (D) Representative sections are shown. Scale bar:
2,000 μm; 200 μm (inset). Original magnification, ×10 (inset).
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Figure 2.9. Biochemical analysis of rTg4510 mice overexpressing FKBP51 or GFP.
(A) Representative Western blot of brain homogenate from FKBP51- or GFP-AAV–
injected mice immunoblotted with FKBP51, pT231, H150 (total tau), and GAPDH. T22
antibody is on complimentary dot blot. (B) Quantification of Western blots (± SEM). #P =
0.03, pT231; *P = 0.05, H150 (total tau); **P = 0.002, T22.
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Figure 2.10. FKBP51 overexpression decreases the accumulation of silverpositive tau. (A) Sections from FKBP51- and GFP AAV–injected mice were stained
with Gallyas silver stain and positive area (± SEM) per CA3 was measured. *P =
0.0297. (B) Representative images of each group are shown. Scale bar: 2,000 μm; 200
μm (inset). Original magnification, ×10 (inset).
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Figure 2.11. FKBP51 selectively promotes tau neurotoxicity. (A) Neurons stained by
cresyl violet and NeuN were counted (± SEM) by stereology in the CA3 region. *P =
0.0003. (B) Representative images are shown. Scale bar: 500 μm; 50 μm. Original
magnification, ×20 (inset). (C) Volume of CA3 (± SEM) in injected transgenic mice was
evaluated by stereology.
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Figure 2.12. FKBP51 is neurotoxic. (A) Murine primary neurons from tau mice were
treated with FKBP51 or GFP AAV9. **p=0.0041 (B) Neuro-2A cells were transfected
with 6TR, P301L tau, FKBP51, or both P301L and FKBP51. **p=0.0064 Toxicity was
measured colormetrically by MTS assay.
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CHAPTER THREE1:
FKBP5 IN THE AGING AND ALZHEIMER’S DISEASE BRAIN

3.1 Abstract
FK506 binding protein 51kDa (FKBP51/FKBP5) is part of a mature heat shock
protein 90kDa (Hsp90) chaperone complex that preserves tau. We have previously
shown that in brains devoid of FKBP51, tau levels are reduced and that high expression
of FKBP51 leads to toxic, oligomeric tau species.

In this study, FKBP51 levels in

human brains were found to selectively increase with age and Alzheimer’s disease,
which correlated with demethylation of the regulatory regions in the FKBP5 gene.
Moreover, FKBP51 levels significantly correlated with Braak pathological staging. We
propose a model where age-associated increases in FKBP51 levels can out-compete
the association of other pro-degradation Hsp90 co-chaperones, resulting in tau
oligomers. Thus, development of drugs which target FKBP51 or related complexes
could be therapeutically relevant for Alzheimer’s disease and other tauopathies.

____________________
1

Portions of this work were previously published (Blair et al, 2013) and are used with permission of the
publisher.
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3.2 Introduction
Alzheimer’s disease (AD) is an age associated disorder hallmarked by the
misfolding and subsequent accumulation of amyloid β (Aβ) plaques and tau
neurofibrillary tangles149. One important measure of AD progression, known as Braak
staging, is measured post-mortem by the accumulation of tau, since tau accumulation is
the best correlated to disease progression11. Tau pathology, although varying in
presentation, has been shown to accumulate in a large number of neurological diseases
known as tauopathies
even

those

150

. The variability in age-of-onset for AD and other tauopathies,

caused by bona-fide

hereditary mutations, indicates that

other

environmental- and experience-based genetic modifiers are involved in the production
of pathogenic tau species151,152. One group of age-affected genes that can also
modulate tau proteostasis is the molecular chaperone family, which includes heat shock
proteins (Hsps), proteins whose expression increase under conditions of stress153.
Levels of Hsps diminish with age, and roles for these proteins in neurodegenerative
disease in relation to the age of onset have been proposed in several models154. In
particular, the Hsp90 system is of interest as a potential tau “toxifier”9,35.
We and others have shown that inhibiting Hsp90 can promote tau clearance,
suggesting that Hsp90 is acting to protect tau in neurons for unknown reasons8,9,155.
Hsp90 can even enhance tau amyloid formation in vitro, a function unique in
comparison to other chaperones. Both of these functions of Hsp90 are in contrast to the
effects of other chaperones that have been shown to enhance tau clearance and
subvert its amyloidogenesis129. Though several co-chaperones of Hsp90 can influence
tau stability in cells, this has not been well studied in the brain. For instance, the FK50649

binding protein 51 kDa (FKBP51/FKBP5) is known to work with Hsp90 to stabilize tau
and regulate tau phosphorylation35, but the mechanisms and pathological relevance for
both of these processes are unknown. FKBP51 possesses properties that are similar to
the cis-trans peptidyl-prolyl isomerase Pin1 that has been reported on extensively156-158;
however much less is known about the role of FKBP51 in the brain despite its genetic
association to human psychiatric diseases78. FKBP51 is a pro-folding Hsp90 cochaperone that forms a complex with Hsp90 via the tetratricopeptide (TPR)
domain159,160, a region also found on other Hsp90 co-chaperones, including the carboxyl
terminus of Hsp70-interacting protein (CHIP/STUB1) and FK506 binding protein 52
(FKBP52/FKBP4)31,122. However, the TPR co-chaperone with the highest affinity for
Hsp90 is FKBP51161. Here we investigate how the FKBP51/Hsp90 complex prevents
tau from clearance, the impact it has on tau pathogenesis, and whether it plays a role in
disease onset due to age-associated changes in TPR protein levels in the human brain.
Our findings suggest that environmental or experiential-based epigenetic changes that
accelerate up-regulation of FKBP51 over time could be a major contributor to the onset
and pathogenicity of tauopathies, and in particular AD.

3.3 Materials and methods
3.3.1 Materials
Antibodies: pT231 (AnaspecTau12 (N-Terminal 2-18; gift from Dr. Lester Binder,
Northwestern University, Chicago, IL), pT231 (Abcam), NeuN (Millipore), H150 (Santa
Cruz), T22 (Dr. Rakez Kayed, University of Texas Medical Branch, Galveston, TX),
Hsp90 (BD Biosciences), GAPDH (Meridian Life Science), FKBP51 (gift from Marc
50

Cox), CHIP (Cell Signaling), FKBP51 (Cell Signaling), and FKBP52 (gift from Marc Cox,
University of Texas at El Paso, El Paso, TX), Actin (Sigma).
Plasmids:

Hsp90α, CHIP, tau, FKBP51 were generated in our lab using the

pcDNA3.1 and pCMV6 backbones.
Human Tissue: Human tissue was obtained from the University of California at Irvine
MIND Alzheimer’s Disease Research Center (Irvine, California). See Tables 3.1 and 3.2
for specific details.

3.3.2 Cell culture and transfection
HEK293 cells were cultured in Opti-Mem plus media supplemented with 10%
FBS and 1% Penicillin-Streptomycin (Invitrogen). DNA transfection and lysis procedures
were followed as described earlier35. In brief, transfections were performed with 2.5 μl
Lipofectamine 2000 (Invitrogen) per 1ug DNA was added to serum-free Opti-MEM for 4
hrs and replaced with serum-containing Opti-MEM for another 44 hrs. For co-IP from
cellular lysates, cells were harvested in co-IP buffer and pre-cleared with protein G
(Pierce) and anti-IgG (species) antibody for 1 hr. After passing through a spin column,
lysates were incubated with Hsp90 antibody for 3 hrs. Protein G was added to the
mixture and incubated overnight on a shaker at 4ºC. The beads were spun down and
washed five times. The precipitate was used for Western blots.

3.3.3 Western blot and dot blot analysis
Samples extracted from cellular lysates and human brain tissues were analyzed
by Western blotting using 10% acrylamide gels43. Antibody dilutions were 1:1000 unless
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otherwise stated. All secondary antibodies were used at 1:1000 (Southern Biotech).
Blots were developed using ECL (Pierce) on a LAS-4000 mini imager (GE Healthcare).
For dot blots, proteins were applied onto a wet nitrocellulose membrane and dried by
vacuum. Once dry, membrane was blocked and developed as described above.

3.3.4 Microarray
Postmortem tissue for biochemical analysis was obtained from 7 different ADR
brain banks by UC Irvine Brain Bank. Microarray analysis was undertaken on 4 brain
regions (PCG, SFG, HPC and EC) from AD cases (n=26, age 74-95, mean age 85.7 ±
6.5 yrs), age-matched controls (n=33, age 69-99 yrs, average age 84.2 ± 6.5 yrs) and
young normal cases (ages 20 to 59; n=22, mean 35.4 ± 10.5 years) using Affymetrix
arrays 9HgU133 plus 2.0 as described previously

162,163

All subjects were evaluated to

be cognitively normal or AD based on diagnoses from medical records. mRNA
expression of each sample was evaluated by gene-chip hybridization as described by
Cribbs et al

163

. These data are deposited on the MIAME-compliant GEO database

(Accession number GSE11882).

3.3.5 Pyrosequencing for DNA methylation status
Tissue from young, aged, and AD samples were homogenized as described
above.

DNA was extracted using Puregene (Quiagen) chemistry and DNA

concentration was measured using Qubit 1.0 Fluorometer (Invitrogen).

Methylation

analysis by bisulfite pyrosequencing was performed as previously described.

164,165

.

Intron 7 was evaluated at six CpG sites: P1_S1_Pos1, P1_S1_Pos2, P1_S2_Pos1,
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P1_S2_Pos2, P1_S2_Pos3, and P1_S3_Pos1. Intron 2 was analyzed at four CpG sites:
P4_S1_CG1, P4_S1_CG2, P4_S2_CG1, and P4_S2_CG2. Methylation in the promoter
region was analyzed for 6 CpG sites: GRE_S1_CG1, GRE_S1_CG2, GRE_S1_CG3,
GRE_S2_CG1, GRE_S2_CG2, and GRE_S2_CG3.

3.3.6 Statistics
To compare 2 groups, a student’s t-test was used. Groups larger than 2 were
evaluated using a 1-way ANOVA test. Linear regression was used to show the
relationship between two variables. P values below 0.05 were considered significant.

3.4 Results
3.4.1 Increasing FKBP51 levels with age allows a shift in Hsp90 functionality
We then sought to determine whether FKBP51 levels could increase with age or
in disease, perhaps linking FKBP51 to tau pathogenesis. FKBP51 mRNA expression
was measured via microarray analyses

163

in young (ages 20 to 59; n=22, mean 35.4 ±

10.5 years) and aged (ages 69 to 99; n=33, mean84.2 ± 8.9 years) non-neurologically
diseased human brain tissue from the following regions: the postcentral gyrus (PCG),
entorhinal cortex (EC), hippocampus (HPC), and superior-frontal gyrus (SFG). FKBP51
expression was significantly increased with age (Figure 3.1A). In fact there was a 3-4
fold increase in FKBP51 expression in all four regions in the aged samples. Hsp90
expression levels were unchanged with aging, with the exception of the SFG, which
showed a significant decrease in expression (Figure 3.1B). Conversely to FKBP51
expression, FKBP52 and CHIP, two other TPR Hsp90 co-chaperones that could
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compete with FKBP51 for binding to Hsp90

161

, had decreasing trends (Figure 3.1, C-

D), but were not significantly decreased with age in any region measured. Additionally,
we found that increasing FKBP51 expression levels were significantly correlated with
age (Figure 3.1E). This was consistent with FKBP51 expression data observed in
human prefrontal cortex through the BrainCloud program152. Similar results were
observed at the protein level in the postcentral gyrus by Western blot (Figure 3.2). Thus,
the aging brain promotes an environment where FKBP51 can dominate the Hsp90
machine, potentially leading to tau pathogenesis
Based on these data, we hypothesized that in human tauopathies, increasing
levels of FKBP51 could allow it to usurp Hsp90 from other co-chaperones with lower
affinity, causing it to produce toxic tau oligomers rather than sequester tau into more
benign amyloid fibrils161. Indeed, in cells expressing constant levels of CHIP, an Hsp90
co-chaperone that can facilitate tau clearance through the proteasome21,47, increasing
FKBP51 levels were able to displace CHIP from Hsp90 and preserve tau levels (Figure
3.3). When taken together, these data suggest that elevated FKBP51 can overtake the
Hsp90 machinery in the aging brain, and alter tau structure in a way that facilitates its
neurotoxic accumulation.

3.4.2 FKBP5 DNA methylation decreases with aging; a mechanism for its increased
expression
It was recently shown that decreases in FKBP5 DNA methylation increase the
expression of FKBP51 164. To see if this was the mechanism leading to the significantly
increased FKBP51 expression found in the aged brain, methylation analysis using
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pyrosequencing was performed on DNA from PCG brain tissue of aging non-demented
samples (N=6) on multiple CpG sites in functional glucocorticoid response elements in
Intron 7, Intron 2, and the promoter (Figure 3.4, A-C) of FKBP591. While Intron 2 showed
no significant linear decrease in methylation with aging, Intron 7 and the promoter had
seven CpG sites for which DNA methylation was significantly decreased with aging.
Significant demethylation in Intron 7 was found at five CpG positions (Figure 3.4A).
Methylation was significantly decreased in the promoter in two locations (Figure 3.4B).
These age-associated decreases in DNA methylation in specific regulatory elements
could explain why FKBP51 expression is progressively increased with age (Figure
3.1E).

3.4.3 FKBP5 expression is further increased in the Alzheimer’s brain, perhaps through
altered FKBP5 DNA methylation
Given the role of FKBP51 on tau accumulation and its pathogenicity, we
examined whether FKBP51 levels were elevated further in Alzheimer’s disease brain
compared to normal age matched controls. FKBP51 mRNA expression was measured
using microarray analyses from the PCG, EC, HPC, and SFG of AD individual
diagnosed brain samples (n= 26, 74-95 yrs old; mean age 85.7 ± 6.5) and age-matched
control samples (n=33, age 69-99 yrs, average age 84.2 ± 6.5 yrs)163. FKBP51
expression was significantly increased in AD diagnosed cases compared to age
matched controls, while the levels of Hsp90 and other TPR containing proteins were
unchanged with disease state (Figure 3.5A). FKBP51 expression was much higher in
younger individuals with AD (aged 70-80), but level of FKBP51 in older individuals with
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AD (>80) were indistinguishable from older non-demented individuals (Figure 3.5B).
This suggests that AD accelerates age-associated FKBP51 up-regulation. Protein levels
were also evaluated in a sub-set of these cases using medial temporal gyrus tissue.
FKBP51 expression was increased in the AD diagnosed cases, compared to the agematched cognitively normal cases (Figure 3.6, A-B). Hsp90 levels appeared unchanged,
while the levels of FKBP52 and CHIP trended toward a decrease in AD cases. In
addition, those samples with higher tau levels, regardless of disease diagnosis, also
had overall higher FKBP51 levels, further supporting a link between FKBP51 and tau
accumulation.
Based on these results, we speculated that increasing FKBP51 levels might
correlate with disease progression or disease onset. To assess this possibility,
correlation analyses were performed based on Braak staging. We chose Braak staging
as the most unbiased measure for disease progression. Indeed, increased FKBP51
levels were significantly correlated with increased Braak staging, suggesting that
FKBP51 may have a role in AD progression (Figure 3.7). In this way, FKBP51 may play
a role in accelerating disease onset and progression by facilitating the production and
accumulation of toxic tau, leading to Alzheimer’s disease and expediting its
pathogenesis.
To evaluate the role of AD on FKBP5 DNA methylation the same pyrosequencing
analyses as described above were performed on brain tissue from the MTG (medial
temporal gyrus) of AD (n=10) and aged-matched controls (n=5). There was a significant
decrease in methylation at 3 CpG sites; one in Intron 7 (Figure 3.8A) and two in the
promoter (Figure 3.8B). There was only one position where DNA methylation was
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increased in the AD population (Figure 3.8C).

There was also a decreasing trend of

overall FKBP5 methylation in intron 7 as well as the promoter areas at every tested
CpG of AD diagnosed samples compared to non-demented aged matched controls
(Figure 3.9).

3.5 Discussion
We show that FKBP5 methylation is reduced both with age and in disease, which
could be one factor leading to increased FKBP51 expression90,164,166. FKBP5
methylation and FKBP51 expression appear to be inversely proportional over time.
Therefore it is certainly conceivable that age could combine with other factors such as
stress or genetic variation to increase FKBP51 expression to detrimentally high levels.
We found that FKBP51 levels were further enhanced in the AD brain compared to agematched controls, possibly resulting from FKBP5 demethylation in these functional
regulatory elements as shown previously

164

. In fact, the progressive increases in

FKBP51 levels correlated with Braak staging in the entire sample population as well as
the non-demented aging sub-population alone. Additionally, since the FKBP5 gene is
responsive to stress hormone164, the levels of which increase in AD167, FKBP51 could
be exploited as a novel biomarker to compliment other such molecules for evaluating
AD risk.
Based on these findings, we predict that people predisposed to increased levels of
FKBP51 could display a higher risk for AD onset and possibly a more rapid progression
of the disease. On the other hand, it is possible that the pathogenic processes that
manifest in AD facilitate increased FKBP51 expression as well, which could also explain
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why FKBP51 levels are further increased in AD compared to age-matched controls.
Either scenario would likely create a vicious cycle in the brain that contributes to
disease progression.
Overall, this study shows that a significant increase in FKBP51 levels in the aged
and Alzheimer’s brain could promote an environment that preserves toxic tau oligomers.
We show that FKBP51 coordinates with the Hsp90 machinery to alter tau structure,
block its degradation and promote abnormal oligomer formation. This strongly
implicates FKBP51 as a therapeutic target for AD and other tauopathies. These data
ultimately shed light on the nature of tau accumulation and support a new body of
research suggesting that chaperone proteins impede rather than aid in the
pathogenesis of these diseases.
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Table 3.1. Human sample data for tissue used in Figure 3.2.

Age
21
36
42
74
85
95

Sex
M
F
M
F
M
M

ApoE
2-3
3-4
3-4
2-3
3-3
2-3

ApoE indicates allelic variant.
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Table 3.2. Human sample data for tissue used in Figure 3.6.
Age Sex

PMI

ApoE

NPDx1

81

M

2.87

n/a

Alzheimer's disease

Tangle
Stage
Stage 6

Plaque Stage

90

F

6.58

3/3

Alzheimer's disease

Stage 6

Stage C

90

M

4.17

3/3

Alzheimer's disease

Stage 6

Stage C

88

F

4.5

3/3

Alzheimer's disease

Stage 5

Stage C

77

M

5.67

2/4

Alzheimer's disease

Stage 6

Stage C

82

F

4.58

3/4

Alzheimer's disease

Stage 6

Stage C

87

M

6.17

3/4

Alzheimer's disease

Stage 5

Stage A

96

F

4.5

3/3

Alzheimer's disease

Stage 6

Stage C

86

M

4.2

3/4

Alzheimer's disease

Stage 5

Stage C

79

F

5

3/3

Alzheimer's disease

Stage 6

Stage C

94

M

3.87

3/3

Normal (Mild Braak Changes)

Stage 1

None

97

M

4

3/3

Normal (Mild Braak Changes)

Stage 2

Stage B

91

F

3.8

3/3

Normal (Mild Braak Changes)

Stage 2

Stage A

96

M

3.58

2/3

Normal (Mild Braak Changes)

Stage 2

None

83

M

1.8

3/3

Normal (Mild Braak Changes)

Stage 2

None

Stage B

PMI indicates post mortem interval. ApoE indicates allelic variant. NPD indicates
neuropathological determination. Tangle stage is used for Braak staging.
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Figure 3.1. FKBP5 expression increases age-dependently in many brain regions.
(A) FKBP51, (B) Hsp90, (C) FKBP52, and (D) CHIP mRNA expression from young (2059) and aged (69-99) samples from the post central gyrus (PCG), superior frontal gyrus
(SFG), hippocampus (HPC), and entorhinal cortex (EC). *p<0.05, **p<0.01, ***p<0.001
(E) The average FKBP5 mRNA expression from all 4 regions for each sample was
plotted against age. P < 0.0001; r = 0.4916.
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Figure 3.2. FKBP51 levles increase with age in the human brain. (A) Human brain
homogenates from the PCG of 4 males (ages 21, 42, 85, and 95 years) were analyzed
by Western blot by FKBP51, Hsp90, FKBP52, CHIP, and GAPDH antibodies. (B)
Quantification of protein levels with aging from multiple blots. FKBP51, P = 0.0765, r =
0.8528; Hsp90, P = 0.394, r = 0.3672; FKBP51, P = 0.9632, r = 0.001352; CHIP, P =
0.0269, r = 0.9469.
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Figure 3.3. Increased FKBP51 alters Hsp90 complexes. Hek cells transfected with
Tau, FKBP51, Hsp90, and CHIP, respectively, were harvested after 48 hours. Following
mouse anti-Hsp90 antibody immunoprecipitation, samples were analyzed by Western
blot for FKBP51, CHIP, Hsp90, Tau 12 (total tau), and GAPDH antibodies, respectively.

63

Figure 3.4. FKBP5 DNA demethylation with aging. Average FKBP5 methylation
analysis of human DNA samples from the PCG of individuals aged 21, 36, 42, 74, 85,
95 years were performed on multiple CpG sites in (A) intron 7, (B) promoter, and (C)
intron 2. Significant demethylation in intron 7 was found at P1_S1_Pos2 (P = 0.0012, r =
0.6506), P1_S2_Pos1 (P = 0.0007, r = 0.9585), P1_S2_Pos2 (P = 0.0039, r = 0.9002),
P1_S2_Pos3 (P = 0.0039, r = 0.9002), and P1_S2_Pos3 (P = 0.0240, r = 0.7583).
Methylation was significantly decreased in the promoter at GRE_S1_CG1 (P =
0.0327, r = 0.7199) and GRE3_S1_CG3 (P = 0.0216, r = 0.7698).
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Figure 3.5. FKBP5 mRNA increases in AD samples. (A) Average mRNA expression
(± SEM) from the SFG, PCG, EC, and HPC of AD and age-matched (69–99 years)
samples. *P = 0.0306. (B) FKBP5 expression correlation with aging in AD and agematched samples.
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Figure 3.6. FKBP51 levels increase in AD samples, leading to chaperone
imbalance. (A) A representative image from Western blot analysis of the medial
temporal gyri of 4 male aged and AD samples. Blots were probed with FKBP51, Hsp90,
CHIP, FKBP52, H150 (total tau), pT231, and actin antibodies. (B) Quantification of total
levels, as they correlate to FKBP51 levels. P = 0.0203, pT231; P = 0.0045, H150 (total
tau); P = 0.0251, T22.
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Figure 3.7. Braak staging correlates with FKBP5 expression. Linear regression
of FKBP5 expression levels with Braak staging in aged (69-99 years) individuals. The
average mRNA expression from all 4 regions for each sample, including demented
(Blue) and non-demented (green) individuals, was plotted against Braak stage. P =
0.0036; r = 0.1774.
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Figure 3.8. FKBP5 methylation is decreased in AD brain. Average methylation (±
SEM) analysis of human DNA from the medial temporal gyrus of AD and age-matched
samples from multiple CpG sites from (A) intron 7, (B) the promoter, and (C) intron 2
of FKBP5. Significant demethylation in AD genotype was found in intron 7 at
P1_S3_Pos1 (*P = 0.0243) and in the promoter at GRE_S1_CG2 (#P = 0.0105) and
GRE3_S2_CG3 (##P = 0.0424). Significant methylation was found in intron 2 at
P4_S1_CG1 (†P = 0.0244).
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Figure 3.9. Methylation analysis in an aging and AD population. Average human
FKBP5 DNA methylation of the medial temporal gyrus from multiple CpG sites from (A)
Intron 7, (B) Intron 2, and the (C) Promoter in AD and aged samples by age.
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CHAPTER FOUR:
THE GENERATION AND CHARACTERIZATION OF rTgFKBP5 MICE

4.1 Abstract
FK506-binding protein 51 kDa (FKBP51), encoded by FKPB5, is an immunophilin
with peptidyl-prolyl isomerase (PPIase) activity. More importantly, FKBP51 contains a
tetratricopeptide repeat (TPR) domain, a motif which can directly bind to Heat shock
protein 90 kDa (Hsp90). We previously showed that viral overexpression of FKBP51
works with Hsp90 to preserve toxic, oligomeric tau. This microtubule stabilizing protein
is known to aberrantly accumulate in a group of neurological diseases known as
tauopathies, the most common being Alzheimer’s disease. Mice ablated for fkbp5 had
lower endogenous tau levels. However, there is not a transgenic model that overexpresses FKBP51 showing the opposite phenotype. For drug discovery efforts to move
forward towards compounds or biological agents that can deplete FKBP51, we have
generated a tetracycline (tet)-regulatable FKBP5 transgenic mouse model. This mouse
model, rTgFKBP5, which shows clear upregulation of FKBP51, will serve as the first-inclass platform to test whether strategies aimed at depleting FKBP51 to identify
treatments directed towards Hsp90/tau complexes.
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4.2 Introduction
FK506 Binding Protein 5 encodes a large molecular weight immunophilin,
FKBP51, known most for regulating in hormone receptor64. There are two important
domains in FKBP51, a tetratricopeptide repeat (TPR) domain for direct Heat shock
protein (Hsp) 90 kDa binding and a peptidyl-prolyl-cis/trans isomerase (PPIase) domain
for isomerase activity and high-affinity binding to immunosuppressive drugs like FK506
and rapamycin63.
The FKBP5 gene has been associated with many psychiatric disorders84. Single
nucleotide polymorphisms (SNPs) have recently been identified to be linked with higher
levels of FKBP5191. These SNPs have also been linked to trauma during childhood
leading posttraumatic stress disorder (PTSD)72, other links include greater risk for
depression168, depressive episodes169, mood disorders170, suicide171 and anxiety
has also been shown to play a role in obesity

173-175

172

. It

and levels of expression have been

shown to correlate with stages of certain cancers176,177. FKBP51 is age-dependently
expressed13,35,89, which is correlated with an increased number and length of psychiatric
episodes in the elderly population. Yang et. al. recently showed overexpressing
FKBP51 using an AAV viral vector caused mice fed a high-fat diet gained more weight
than their control littermates, and this weight gain was associated with decreased
glucose tolerance coupled with high corticosterone levels173.
FKBP51 has been well characterized in regards to the stress hormone system
that controls the hypothalamic/pituitary/adrenal (HPA) axis71. FKBP51 serves to reduce
the activation of the glucocorticoid receptor (GR) by cortisol, the primary stress hormone
in humans178. This inhibition results in diminished movement of GR into the nucleus,
71

which changes the rate of transcription of many genes, ultimately allows us to cope with
acute stress179. During normal acute stress, GR activation attenuates the HPA-axis
stress response through a feedback inhibition cycle. However, too much FKBP51 can
slow this process down, allowing cortisol levels to accumulate and stimulate other
untoward physiological effects180. Inversely, the consequence of prolonged activation of
the HPA-axis has many negative outcomes, most overlapping with those found in risk
SNP carriers.

These outcomes include weight gain181, depression182, suicidal

tendencies183, PTSD184,185, psychosis186, and even altered immune function

187

. In

addition to these psychopathologies, our group recently ascribed a role for FKBP51 in
tau biology13,35.
In our first FKBP51 focused study, we found that tau metabolism was drastically
altered in the presence of very high or low levels of FKBP5135. In other words, in
circumstances of FKBP51 knock-down tau levels were significantly reduced, and in the
presence of FKBP51 overexpression tau levels were preserved. In our follow-up study,
we found that FKBP51 levels increase dramatically with aging and correlate to
increased tau accumulation in the human brain13. We were able to characterize this
preserved tau as a phosphorylated, oligomeric, and toxic species. Thus, FKBP51 may
prove to be an important therapeutic target for drugs aimed at altering tau metabolism.
We and others have employed mice that do not produce any FKBP51 to test
whether deletion of this important gene could reduce susceptibility to trauma-induced
psychopathologies. In behavioral paradigms similar to extreme physical conditioning
and situational hopelessness in humans, mice lacking FKBP5 (FKBP5 -/-) showed more
resiliency compared to wild-type littermates89,188,189. Induction of corticosterone levels
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(the rodent equivalent of human cortisol) was significantly attenuated following stress in
these FKBP5-/- mice. In this way, the lack of FKBP51 was enhancing the brain’s
responsiveness to and/or production of corticosterone. Importantly, the mice lacking
FKBP51 were otherwise behaviorally intact: They had no memory or motor deficits and
there were no abnormal gross pathologies observed. Moreover, we have additional data
showing that these mice have normal blood glucose levels, white blood cell counts and
body mass despite these alterations in psychological resiliency and corticosterone
production. This suggests that FKBP51 is most important for the brain's response to
cortisol and other deleterious peripheral consequences associated with cortisol overproduction may not occur. While knockout mice provide the proof-of-concept that this is
a feasible strategy, there has not been a transgenic model that over-expresses FKBP51
until now. For drug discovery efforts to move forward towards compounds or biological
agents that can deplete FKBP51, a transgenic model that recapitulates stress-induced
depressive-like phenotypes due to FKBP51 over-expression is needed.
We have developed a transgenic mouse over-expressing FK506 Binding Protein
51 (FKBP51) selectively in the brain, which will be a highly valuable tool for future drug
discovery efforts aimed at altering tau metabolism, and also for strategies for improving
psychological resiliency after trauma. Exposure to traumatic events can lead to stressinduced psychological disorders including depression, suicide, bipolar disorder,
peritraumatic dissociation, aggression and post-traumatic stress disorder (PTSD). This
mouse model may be beneficial in look for therapeutics for each of these
psychopathologies. Naturally-occurring genetic variants in the gene encoding FKBP51
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(FKBP5) increase susceptibility to these disorders often by increasing FKBP51
levels72,75,78,171,190-195.
The creation of this mouse model overexpressing human FKBP51 will be
beneficial in measuring the consequences of changes in FKBP51 expression with aging
and also the higher levels found associated with SNPs. It would have implication in not
only tau research but also depression, stress, cancer, and obesity research. The only
model of increased FKBP51 expression reported is the naturally occurring increased
levels found in New World monkeys known to have an increased resistance to
glucocorticoids. There are great limitations to studying no-human primates, and a small
rodent model would be better suited.

4.3 Materials and methods
4.3.1 Ethics statement
All studies were carried out following the guidelines set by the University of South
Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance with the
Association for Assessment and Accreditation of Laboratory Animal Care International
(AALAC) regulations.

4.3.2 Construction of the tet-controlled FKBP51 vector
Transgenic construct was generated by cloning a human FKBP51 cDNA a TetOp-mp1pA vector. A PmeI site was added into the mp1 pA vector (gift from Noreen
Luetteke) and ligation of the FKBP51 cDNA in the vector with ClaI and EcoRV.
Successful ligation was confirmed using a digestion to identify FKBP51 via gel
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electrophoresis. This construct was then subcloned into a pBT378 (gift from Noreen
Luetteke) vector using PmeI and NotI restriction sites and then confirmed by gel
electrophoresis.

4.3.3 Cell culture
HEK293 cells were grown in Opti-MEM with 10% FBS and 1% PenicillinStreptomycin (Invitrogen). DNA transfections were performed using 2.5 µ Lipofectamine
2000 (Invitrogen) in serum-free Opti-MEM, following cells were incubated for 24 or 48
hours as indicated before harvest. Cells were harvested in MPER buffer supplemented
with protease inhibitor, phosphatase inhibitors and PMSF, incubated on ice for 20
minutes, centrifuged, and supernatants were used for Western blotting.

4.3.4 Generation of rTgFKBP5 mice
The final transgenic plasmid was microinjected combined with ΦC31 integrase
mRNA (Invitrogen) into isolated fertilized mouse (FVB/N) oocytes which have the
matching attP integrase sites.

Successfully injected eggs were re-implanted into

pseudo-pregnant females. Micro injections and founder mice were generated in the
Stanford Transgenic Research Center and shipped to the University of South Florida for
genotyping and characterization.

4.3.5 Genotyping of bigenic mice
Mouse genotypes were determined by PCR followed by DNA electrophoresis.
Briefly, ear clips were digested overnight and then amplified by PCR using HotStarTaq
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Plus Master Mix (Qiagen), betaine and dye with in two separate reactions. The first
amplification was amplified by forward and reverser primers for the human FKBP5 gene
(F, 5’GTGTACGGTGGGAGGCCTAT3’, and R, 5’GTCCCATGCCTTGATGACTT3’) and
housekeeping

gene

T-cell

receptor

delta

chain

(Tcrd)

(F,

5’-

CAAATGTTGCTTGTCTGGTG-3’, and R, 5’-GTCAGTCGAGTGCACAGTTT-3’) to
confirm presence of tissue. Genomic DNA was amplified by PCR in a thermocycler
(Eppendorf) using the following conditions: 95°C for 15 minutes; 30 cycles of 95°C for
15 seconds, 68°C for 30 seconds and 72°C for 45 seconds; followed by 11 cycles of
95°C for 15 seconds and 50°C for 30 seconds, and 72°C for 45 seconds; and then 10
minutes of 72°C. The second amplification was amplified by forward and reverser
primers for the CamKIIα tTA (F, 5’CGCTGTGGGGCATTTTACTTT3’, and R, 5’CATGTCCAGATCGAAATGGTC-3’) and housekeeping gene Tcrd. Genomic DNA was
amplified by PCR in a thermocycler (Eppendorf) using the following conditions: 95°C for
15 minutes, and 20 cycles of 95°C for 15 seconds, 68°C for 30 seconds and 72°C for 45
seconds; followed by 10 cycles of 95°C for 15 seconds, 50°C for 30 seconds, and 72°C
for 45 seconds; and then 10 minutes of 72°C. PCR product was then run on a Qiaxcel
(Qiagen) and also by gel electrophoresis on a 2% agarose gel for analysis.

4.3.6 Tissue collection
At sacrifice, mice were weighed and overdosed with a pentobarbital solution and
transcardially perfused with 0.9% saline solution until brains were clear of blood. Brains
were carefully removed and dissected into hemispheres.

The left hemisphere was

immediately submerged into fresh 4% paraformaldehyde solution for 24 hours and
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stored in DPBS supplemented with azide solution until sectioned. The right hemisphere
was subdivided into anterior cortex, posterior cortex, hippocampus, striatum, cerebellum
and the rest of the brain, which was quickly put into labelled cryotubes, capped, and
flash frozen using dry ice and ethanol.

4.3.7 Biochemical analysis of tissue
Brain bits used for biochemical analysis were kept frozen when weighed and
homogenized using a tissue homogenizer (IKA) for 30 seconds in 50mM Tris Base,
274mM NaCl and 5mM KCl at pH 8.0, supplemented with protease inhibitor for tissue
(Sigma), phosphatase inhibitors and PMSF. This was followed by 20 pulses of
sonication. Samples were then kept on ice for 15 minutes and centrifuged at 13,000 x g
for 15 minutes. Supernatants were transferred to a new tube and used for Western
blotting

4.3.8 Western blotting
BCA protein estimation was performed on tissue and cell lysates used for
Western blots. Samples were denatured and run on 10% acrylamide gels. All primary
and secondary antibodies were used at 1:1000 dilutions. Blots were developed on a
LAS-4000 imager (GE Healthcare) using ECL (Pierce).

4.3.9 Immunohistochemical analysis of tissue
Fixed tissue was submerged in 10%, 20% and 30% sucrose for 24 hours. Once
the brains acclimated to the 30% sucrose, tissue was sectioned 25µM think on a
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freezing stage using a sliding microtome. Sectioned tissue was submerged in DPBS
supplemented with 0.2% sodium azide.

4.4 Results and discussion
4.4.1 Generation of the rTgFKBP5 mice
The responder transgene (Figure 4.1) was created by cloning a human FKBP51
cDNA into a tetracycline-inducible vector called Tet-Op-mp1pA. This was achieved by
the addition of a PmeI site into the mp1 pA vector (gift from Noreen Luetteke) via
mutagenesis. Second, we digested the vector with ClaI and EcoRV to ligate in FKBP51.
This vector is a pBluescript II SK phagemid that contains bacteria derived tetracyclineresponsive promoter element (TRE). This element is comprised of the Tet operon
(TetO), seven identical repeats of a 19 bp tet operator sequence, followed by a human
derived minimum CMV (cytomegalovirus) promoter. This TetO At the 3’ end of the
vector a 0.5kb fragment comprised of a mouse protamine-1 gene intron (Mp1) and a
polyadenylation (pA) sequence located downstream of the inserted FKBP51 stabilize
the cDNA196. The Tet-op-mP1 was used to make a successful tetracycline regulatable
epidermal growth factor receptor (EGFR) transgenic mouse model197. To prevent
transcription interference with the transgene, a 2.4kb fragment containing two copies of
the chicken beta-globin insulator (cHS4) was subcloned upstream of the TetO
sequences. This insulator has been shown to dramatically increase the expression of
the subsequent cDNA sequence198 and protects against DNA methylation199. The TetOFKBP51 transgene will be cut out using the added PmeI and existing NotI restriction
sites and subcloned into a vector called pBT378 (gift from Noreen Luetteke) in between
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two bacteriophage derived attB sites that are recognized by the phage ΦC31
integrase200,201. The flanking by attB sites allow for a high efficiency single-copy
insertion of the gene into the Hip11 locus on chromosome11202. PhiC31 intragese will
be used to direct integrations into the attP-tagged permissive genomic site for reliable
expression as shown in Figure 4.2.
The effectiveness and tet-responsiveness of the plasmid were evaluated in cells
stably expressing the tet-repressor (Figure 4.3). HEK cells were transfected with
indicated amounts of FKBP51 responder (51Rspd; Figure 4.3A), and tet-repressor (TR;
Figure 4.3B) or tet-transactivator (tTA; Figure 4.3C) for 24 hours. Cells were then
treated with indicated concentrations of tetracycline for 48 hours and lysates were
analyzed by Western blot for FKBP51 and GAPDH. The construct behaves as expected
in culture, in other words the FKBP51 responder (Figure 4.3A) dose dependently
increases the levels of FKBP51. The Tet-repressor (Figure 4.3B) blocks expression of
FKPB51, which then can be rescued dose dependently by tetracycline, mimicking what
would happen when crossing a mouse made with this construct to rtTa mice. The tettransactivator (Figure 4.3C) drives FKBP51 expression, which can then be shut off by
treatment with tetracycline, demonstrating what would happen when crossing a mouse
with this vector with a tTa mouse (Figure 4.4). Following confirmation of the vector,
pronuclear injections were performed by Stanford University and founders were
received and genotyped. Four of the twenty-five mice were positive for the responder
gene.
We then crossed mice expressing the responder transgene onto tetracycline
activator line following the tTA (tetracycline-controlled transactivator) system as first
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described by Gossen and colleagues203. The tTA is comprised of an Escherichia coli
derived Tet repressor (TetR) DNA binding sequence from the transposon Tn10 fused to
a VP16 protein made from Herpes Simplex Virus. In the heterozygous offspring, the
TetR will bind to the tetO operator sequence and drive transcription. The addition of
tetracycline will cause the repressor to disassociate from the Tet operon preventing
TRE driven transcription (Figure 4.5) 204. To drive the expression of FKBP51 in forebrain
neurons, we crossed the mice with a calcium/calmodulin-dependent protein kinase II
alpha (CamKIIα) tTA line. This line contains an activator transgene made of a tet-off
open reading frame followed by a Ca2+/calmodulin dependent protein kinase II promoter
element205. This promoter drives high expression primarily in the grey matter of the
forebrain neurons; primarily in the forebrain and hippocampus205,206.

4.4.2 Analysis of FKBP51 overexpression
In order to confirm over overexpression of FKBP51, we analyzed tissue
homogenates from one month rTgFKBP5 mice and non-transgenic littermates by
Western blot and staining. Western blot analysis of the anterior cortex showed clear upregulation of FKBP51 (Figure 4.6) compared to wild-type littermates. We then looked at
the FKBP51 levels in discrete regions of the brain in a 4 month rTg4510 mouse (Figure
4.7) including the hippocampus (HPC), striatum (STR), anterior cortex (ACX), posterior
cortex (PCX), the rest of the brain not subdivided (ROB) and the cerebellum (CER). We
found that expression was highest in the hippocampus, followed by the posterior cortex,
then the anterior cortex and striatum. There was mild over expression in the “rest of
brain” bit. This is most likely not the level of expression in that entire brain region, but
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an average of regions of high expression and low expressing mixed together, further
analysis of tissue need to be done to look at levels throughout the mid brain. The
cerebellum showed no detectable overexpression of FKBP51, as expected from the
expression pattern of the CamKIIα promoter. To look at the expression pattern in the
hippocampus and the cortex of these mice we stained for FKBP51 (Figure 4.8). This
staining confirmed high FKBP51 overexpression throughout the hippocampus and
anterior cortex of the rTgFKBP5 mouse model.
This new mouse model, which is the first to over-express FKBP51, will allow for
an extensive characterization of the behavioral and biochemical effects of excess
FKBP51. Since we designed the mice with a tet-regulatable system, we can alter this
system depending on the chosen mate. Depending on the mate selected the expression
of FKBP51 can either be constant over-expression (Tet-Off) or a drug dependent
overexpression (Tet-On). The expression locations can be selected by using different
promoters on the tet-expressing mice. This system will allow the study of sudden higher
expression of this protein in discrete and specific tissue or high overexpression
ubiquitously throughout the mouse. This novel model will also serve as a testing
platform for new therapeutics which target FKBP51 for the treatment of tauopathies and
other psychopathologies.
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Figure 4.1 Key elements in the vector. The inserted gene will be tet-regulatable by
the Tet-operon after crossing with a mouse expressing a tet-transactivator (tTA) or a tetrepressor (rtTA). Continual minimal expression will be driven by the minimal
cytomegalovirus (CMV) promoter just before the FKBP5 human gene. This expression
will be stabilized by an Mp1 polyadenylation tail.

Figure 4.2 Schematic depicting the detailed transgene inserted to generate
rTgFKBP5 mice. This tet-regulatable vector will be specifically inserted by the flanking
attB sites via a PhiC31 integrase into the mouse genome in chromosome 11. The
inserted DNA will have stable expression due to the upstream cHS4 insulator and
downstream Mp1 polyA tail. The tet-operon repeats allow a tet-transactivator/repressor
regulation of the minimally expressed, due to the minimal CMV promoter, human
FKBP51.
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Figure 4.3. The engineered tet-responsive FKBP5 construct behaves as expected
in HEK cells. HEK cells were transfected with indicated amounts of FKBP5 responder
(51Rspd; A) and Tet-repressor (TR; B) or tet-transactivator (tTA; C) for 24 hours. Cells
were then treated with indicated concentrations of tetracycline for 48 hours and lysates
were analyzed by Western blot for FKBP5 and GAPDH.
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Figure 4.4. tTA regulation schematic. This schematic depicts the Tet-off system in
which the tet-transactivator (tTA) binds to the tet-response element (TRE/tet-operon)
and drives high expression of FKBP51. Upon treatment with doxycycline (Dox), the tTA
is bound by Dox, preventing activation of the TRE and halting subsequent upregulation
of the FKBP5 gene.
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Figure 4.5. Making bigenic rTgFKBP5 mice. Tet-transactivator (tTA) mice controlled
by the CamKIIα promoter were crossed with mice expressing FKBP51 under control of
the tet-responder element (TRE). These Tet-off mice will overexpress human FKBP51
in CamKIIα expressing cells. FKBP51 overexpression is shut off by treatment with
doxycycline (Dox).
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Figure 4.6 FKBP51 levels in the rTgFKBP5 mice. Western blot analysis of FKBP51
levels in the anterior cortex of rTgFKBP5 and non-transgenic mice.

Figure 4.7 FKBP51 levels in various brain regions of rTgFKBP5 mice. Western blot
analysis of FKBP51 levels in the hippocampus (HPC), striatum (STR), anterior cortex
(ACX), posterior cortex (PCX), the rest of the brain not subdivided (ROB) and the
cerebellum (CER).
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Figure 4.8. Distribution of FKBP51 overexpression in rTgFKBP5 mice. Fluorescent
staining was performed to detect FKBP51 in the brains of non-transgenic and
rTgFKBP51 mice. Images of the hippocampus (CA1, CA3, dentate gyrus) and anterior
cortex (CTX) are shown. Scale bar represents 200 um.
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CHAPTER FIVE:
FINAL CONSIDERATIONS

This study validates Hsp90 co-chaperone, FKBP51, as an important regulator of
tau metabolism. The major findings of this study demonstrate that FKBP51 coordinates
with Hsp90 to preserve tau in a state that is 1) unable to be degraded by the 20S
proteasome, 2) low in β-sheet structure, 3) highly phosphorylated at threonine 231, 4)
oligomeric, and 5) neurotoxic. We have clearly shown that FKBP51 levels in the human
brain increase with aging. Aging is the greatest major risk factor for Alzheimer’s disease
(AD) and many tauopathies207. This work, combined with that of the Rein lab161, shows
that FKBP51 can usurp Hsp90 from other co-chaperones to promote tau accumulation.
This study supports the idea of identifying drugs which target Hsp90 through FKBP51
modulation as a therapeutic option for the treatment of AD and other tauopathies.
Another key result of this study is the generation of a novel, tet-regulatable FKBP51
overexpressing mouse model. This model can now be used to test therapeutics, as
they are identified, which target FKBP51 for their effectivenes in vivo.
It has been known for quite some time that modulating Hsp90 can affect the
degradation of tau9. Hsp90 inhibitors, as described in Chapter 1, have repeatedly shown
that the inhibition of the Hsp90 ATPase leads to the degradation of tau. Many of these
small molecule inhibitors have now entered or completed clinical trials (Table 1.2)
88

primarily for the treatment of several forms of cancer208-210. Many of these clinical trials
are still in progress, but a number of them have failed due to toxicity and
bioavailability208. Additionally, since many Hsp90 inhibitors are developed for the
purpose of treating cancers which are found in the periphery210, so blood-brain barrier
(BBB) permeability is not necessary considered in the design. In fact, Hsp90 inhibitors
which cannot cross the BBB may be optimal for the treatment of peripheral diseases to
limit off-target central effects. However, for the treatment of AD and other tauopathies,
BBB permeability is necessary for a peripheral route of treatment, which is preferred.
While treating tauopathies through Hsp90 inhibition is still promising based on steady
advancements in the development of small-molecule inhibitors. However, any inhibitor
targeting Hsp90 is still likely to have many off target effects, given the many roles of this
major chaperone3. This study supports the idea of taking a more targeted approach in
regulating the functions of Hsp90 through FKBP51, a co-chaperone with more limited
functions in the cell, especially given the lack of a negative phenotype in FKBP5-/mice89.
This approach has clear limitations, since there are currently no drugs available
which specifically target FKBP51, over its homolog FKBP52. However, with the creation
of mice overexpressing FKBP51, in vivo testing will now be expedited once drugs are
identified. It is unlikely that drugs designed to inhibit the PPIase domain of FKBP51 will
have potent effects on tau pathology, since tau levels were still preserved following
overexpression of a PPIase null mutant of FKBP5135. Further studies on the effects of
the PPIase domain of FKBP51 need to be performed to confirm this. It is conceivable
that the phosphatase activities of FKBP51 dephosphorylate tau in specific sites which
89

lead to toxic oligomerization instead of silver positive tangles. Previous work from our
lab showed that using a PPIase null FKBP51, with a F130A mutation, still led to
accumulation of similar tau species as with overexpression of wild-type FKBP51 with a
few exceptions

35

. The PPIase null FKBP51 showed further increased phosphorylation

of tau at pS396/pS404, pS212, and pT231 compared to wild-type FKBP51, while both
showed substantially higher tau accumulation and phosphorylation than the control
without FKBP51 overexpression. In addition to these sites, tau was highly
phosphorylated at pS262/S356, the main site of MARK2 phosphorylation, which was not
detectable with wild-type FKBP51 treatment. More studies with PPIase mutants of
FKBP51 are needed in order to fully understand the role of the PPIase domain in
regulating tau.
If the PPIase domain proves to have little effect on tau biology, drugs will need to
be identified or synthesized to decrease FKBP51 levels, either by increased
degradation or decreased transcription to have a higher potential of affecting tau
metabolism.

Drugs which modulate the FKBP51/Hsp90 complex or the binding of

FKPB51 and Hsp90 also have potential to be therapeutically active in the treatment of
AD. The development of drugs which target FKBP51 in any of these ways may also
prove to be effective in treating the deleterious effects of FKBP51 found in many
psychopathologies and cancers. The rTgFKBP5 mouse model, generated in this study,
will serve as therapeutic platform to test these drugs in vivo.
This study was inconclusive in the ability of FKBP51 to decrease age of onset of
AD. This was a limitation due to the age of onset being unavailable from the samples
used for the mRNA studies. We would predict that age of onset of AD is accelerated by
90

increased FKBP51 levels, based on the correlation of FKBP51 to an increase in many
disease relevant types of tau shown in Figure 3.613.
FKBP51 SNPs, although implicated to increase risk for many diseases84,211, has
not been linked to AD or other tauopathies. This was outside the scope of this study,
but would be interesting to look at in future studies, in regards to age of onset, tau
accumulation, neurodegeneration, and FKBP51 levels. This could also be done in a
subpopulation of people with risk SNPs in FKBP5 which also have AD, if there is no
SNP that is identified to increase risk for AD in the population as a whole. In addition,
the mechanism of demethylation of the FKBP5 DNA, or the conclusion that this was the
only mechanism leading to increased FKBP51 with aging, was not identified in this
study.
The roles of glucocorticoid receptors (GR) and tau212 and the role of GR and
FKBP51

13

have now been clearly studied. A combined study of the role of FKBP51

regulation of GR combined with tau pathology has not been performed, to date.
Another pathway which has been studied separately is the role of FKPB51 in regulating
AKT and the role of AKT in regulating tau. Given the central role of Hsp90 to both
FKBP51 and AKT213, there is a clear link between these pathways which are implicated
in both neurodegenerative diseases and cancers. More studies are needed to
determine the role of FKBP51 and AKT together in tau biology.
Overall our findings suggest there is an age-associated imbalance in the
chaperone network, which could lead to toxic accumulation of tau. This work validates
FKBP51 as a potential therapeutic target for the treatment of AD and other tauopathies.
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Furthermore, the efforts of this study generated the first FKBP51 overexpressing mouse
model to serve as a platform for the testing of new drugs as they are discovered.
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APPENDIX B:
IMMUNOHISTOCHEMISTRY HANDBOOK

B.1 Order of events to prepare and process tissue
1. Perfusion and preparation of brain tissue
a. Mouse Perfusion with 0.9% Saline
b. Tissue harvested for staining will be fixed in 4% paraformaldehyde for <24
hours.
c. Long-term storage of tissue in DPBS + 0.65% azide solution
2. Cryopreservation and sectioning
a. Before sectioning tissue for staining tissue is cryopreserved in sucrose
gradients over 3 days.
i. 10% sucrose for 24 hours
ii. 20% sucrose for 24 hours
iii. 30 % sucrose for 24 hours
b. Sectioning (once the brain sinks in the 30% sucrose solution) is done by a
sliding microtome with a freezing stage.
3. Free-floating staining of proteins of interest, either brightfield or fluorescent.
4. Stained tissue is mounted in mounting solution on charged glass slides and left
to dry overnight
5. The next day, tissue is dehydrated in serial ethanol solutions followed by clearing
with histoclear before coverslipping using DPX and allowed to dry overnight
6. Imaging is usually done using a Mirax slide scanner microscope after the slides
have dried for at least 2 days.
7. Images made by the slide scanner are segmented using NearCYTE for desired
regions of interest
8. Segmented slides are batched analyzed for positive staining
9. Analysis produced by IAE is sorted and analyzed by mouse and genotype and
put into graphs
10. Representative images are made to represent the results of the analysis
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B 2 Perfusion and brain tissue preparation
B2.1 Perfusion and fixing
Mice are perfused transcardially using 20-50 mL of 0.9% saline until brain tissue is
clear. The brain is removed and stored for the appropriate technique. Most commonly
the brain is divided down the midline, the right half of the brain is snap frozen cryotubes
in dry ice or liquid nitrogen. The left hemisphere is put directly into 4%
Paraformaldehyde (PFA) solution, where it will stay for up to 24 hours. PFA creates
crosslinks between aldehyde bonds, so the proteins stay in place as they were in the
brain. The ideal fixing time for this tissue is between 6 and 24 hours, never fix for more
than 24 hours. Before the 24 hour mark, PFA should be decanted off and replaced with
DPBS + 0.65% azide solution for long-term storage of the tissue.
***Handling mice, which includes this process, requires IACUC certification and
training on handling and euthanatizing mice.

Figure B1. Subdividing the brain for IHC and biochemistry
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B 2.2 How to properly label tubes:
Fixed tissue will go in these vials:

Figure B2. Labelling tubes for fixed tissue
These should be labelled on the lid and side with the study name/mouse number and
the date in dark, thick sharpie as shown. Always write VERY clearly!
Snap-frozen tissue will be placed in cryotubes:

Figure B3. Labelling tubes for snap-frozen tissue
These tubes should be color coded as they are labeled, including: study name/mouse
number on the top in dark thin sharpie and name/mouse number, date, and the region
(as described below) on the side
Table B1: Cryotube Labelling Code
Tube cap color Region
Write on side
Red
Hippocampus HPC
Orange
Striatum
STR
Green
Anterior
ACX
Cortex
Yellow
Posterior
PCX
Cortex
Blue
Cerebellum
CER
Purple
Rest of brain ROB
B 3 Cryopreservation and sectioning
114

B 3.1 Cryopreservation
Before staining, the brain tissue must be sectioned. In order to prepare the tissue
for sectioning, tissue must first be cryopreserved in sucrose gradients over 3 days.
DPBS + sodium azide is decanted from the brain tissue and replaced with 10%
sucrose and allowed to sit overnight. This process is repeated for two more days with
20% and 30% sucrose solutions. Once the brain is at the bottom of the 30% sucrose
solution, the brain is ready to be sectioned. This sucrose gradient pulls water out of the
vessels in the brain and allows the brain to freeze without bursting these. This process
is important; it prevents ice crystals from forming in the tissue. If the tissue is not
properly preserved, it will cut poorly, be fragile, and break apart. As sucrose gradients
are changes, this should be noted on the top of the brain tubes using tick marks
representing each 10% of sucrose added to the tube. This allows for less confusion,
especially when working on the same study with multiple people.

Figure B4. Tick marks to show progression of fixed tissue through sucrose
Sectioning is done on a sliding microtome with a freezing stage. Please see the
following protocol for the full procedure, but I will walk you through the process now.
First make sure you have plenty of chilled DPBS + 0.65% azide ready and at the
correct pH. The brain is placed in freezing medium on a freezing stage, connected to a
chilled water bath. This brain pictured below has been placed to section horizontally
(i.e. the top of the brain as it sits in the mouse is still the top on the freezing stage). If
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the brain is a hemisphere and not whole, there should be a clean cut down the center
of the brain, this should always be perpendicular to the freezing stage, as shown in the
picture below. They will be white all the way through when completely frozen.

Figure B5. Examples of horizontal tissue on freezing stage. (A) Half brains placed
in glue waiting to freeze. (B) Frozen half brains and (C) whole brains which have been
sectioned horizontally.

116

B 3.2 Sectioning
B 3.2.1 Setting up
The brain is sectioned at 25 µm into 24-well plates 2/3 filled with DPBS + 0.65%
azide in each well. Trays should be labelled on the top with the name of the cohort
name/mouse number, your initials, tray number/total trays, date, and double thick
sectioned marked when appropriate. The trays should also be labelled on the side with
the cohort name/mouse number. When filling with DPBS + 0.65% azide, use a 25 mL
serological pipet and pipette filler and make sure the solution is chilled and at pH 7.4.
The pH of this solution is very important. 24-well plates need to be non-treated, or else
the tissue will adhere to the bottom and be ruined. Always keep plates flat once filled.
Tilting will cause tissue to be displaced from well
Half brains need to be placed on the stage very carefully, as to not let them fall over
in the glue. Hold them vertical if necessary until the glue is frozen.
Whole brains need to sit flat on the stage and will need to have a fiduciary mark
(nick) put in the left side of the brain, as shown below.

Figure B6. Fiduciary mark placement

Figure B7. Important parts of the sliding microtome.
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B 3.2.2 How to turn on the water bath

Figure B8. How to turn on the water bath.
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B 3.2.3 Sectioning horizontal sections
1. At least 30 min before you are going to start, make sure the chiller is turned on
and set to 5°C before you start (see B3.2.2)
2. Set up:
3. Make sure microtome is set to 25 um slices. Adjust stage so the blade is above
the stage with enough clearance so you can put the brain on and start at the top.
4. Attach blade at about a 3° angle and as firmly as is possible.
5. Place a cut square of paper towel on the stage, wet with water (not ethanol!)
6. Always use flat sided forceps to handle brain
7. Put brain on lid of vial in the appropriate position, so it is easy to put on the
freezing stage
8. If needed, trim brain stem so brain will be sitting evenly.
9. Place a small amount of Tissue-Tek glue on the paper towel.
10. Carefully place brain on glue. It should be a flush horizontal and as straight
vertical as possible. Turn on freezing unit. The button is in the back right of the
machine. Double check to make sure it is set to cool to -18C. If needed, hold
the brain with forceps until the bottom is frozen to ensure brain is sitting correctly.
a. If working on more than one brain at a time put the brains in numerical
order to avoid confusion.
b. Do not section more than one brain at a time, until you are ready to do so.
11. Cover brains with a weigh boat or bottle cap until frozen (this usually takes about
15-20 min).
a. Brain tissue will turn very white once completely frozen.
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12. Any frost buildup can be brushed away with a makeup brush (used just for that
purpose).
13. Now adjust stage so blade is just above tissue and then roll forward and back
until you slice the first piece of tissue. It will be tiny.
a. When moving over the tissue, move blade at a slow and steady rate. It
should be very even as you pass through the tissue to get nice, even
slices.
b. The blade should be very dry as it goes through the tissue, so dry the
blade with a Kimwipe after each pass through the brain.
14. Cut 25 sections and discard these (we collect the 26th onwards). You will always
hear a click when the stage moves up 25 um
15. On the 26th section, wet paintbrush and in one motion roll/swipe the tissue off the
blade. This should be done smoothly in one motion to avoid tearing any sections.
Place tissue in the bottom of the appropriate well. Floating brain sections can
dehydrate (and therefore become useless). Wipe blade, roll blade back (should
always hear a click) and then proceed with the next section.
a. Always have a dry blade and a wet paintbrush when sectioning, this will
reduce damage to the tissue
16. Continue sectioning until the whole brain is complete (once the brain is in 2
pieces).
17. Remove blade and put into oil or rust resistant paper, thaw the stage, wipe
everything down, turn off water chiller and freezing unit. Cover the microtome.
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Put parafilm (2 ½ squares long, 2 squares wide) over the wells of the plate, then
secure the lid of the plate. Store at 4C until needed.
18. Never tilt trays, always keep them flat!
a. If you are sectioning more than one brain at a time, place the tissue in
numerical order as you would read it, so you won’t forget which brain is
where.
b. Always clean up the area around the microtome, the sucrose can bring
ants if not properly cleaned. Rinse bench with water followed by 70%
EtOH.
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B 3.4. How to place sections into trays
Table B2. Tray placement for tissue sectioned sequential no stereology: for
injection studies.
Place 24 well plates horizontally
Depth
(μm)
1
3
5
7
9
11
13
15
17
19
21 23 25μm 1225
2
4
6
8 10
12
14
16
18
20
22 24
25 27 29 31 33
35
37
39
41
43
45 47 25μm 1825
26 28 30 32 34
36
38
40
42
44
46 48
49 51 53 55 57
59
61
63
65
67
69 71 25μm 2425
50 52 54 56 58
60
62
64
66
68
70 72
73 75 77 79 81
83
85
87
89
91
93 95 25μm 3025
74 76 78 80 82
84
86
88
90
92
94 96
97 99 101 103 105 107 109
98 100 102 104 106 108 110
121 123 125 127 129 131 133
122 124 126 128 130 132 134
145 147 149 151 172 174 176
146 148 150 170 173 175 177
189 191 193 195 197 199 201
190 192 194 196 198 200 202
Section 1 here is really the 26th section

111
112
135
136
178
179
203
204
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113
114
137
138
181
182
205
206

115
116
139
140
183
184
207
208

117
118
141
142
185
186
209
210

119
120
143
144
187
188
211
212

25μm

3625

25μm

4225

25μm

4825

25μm

5425

Table B3. Tray placement for tissue sectioned sequentially with stereology every
8th section: for injection studies.
Place 24 well plates horizontally (Section 1 here is really the 26th
section)
Depth
(μm)
1
3
5
7
9 11 13 15 17 19 21 23 25μm
1300
2
4
6
10 12 14
18 20 22
25 27 29 31 33 35 37 39 41 43 45 47 25μm
1975
26 28 30
34 36 38
42 44 46
49 51 53 55 57 58 61 63 65 67 69 71 25μm
2650
50 52 54
58 60 62
66 68 70
73 75 77 79 81 83 85 87 89 91 93 95 25μm
3325
74 76 78
82 84 86
90 92 94
97 99 101 103 105 107 109 111 113 115 117 119 25μm
4000
98 100 102
106 108 110
114 116 118
121 123 125 127 129 131 133 135 137 139 141 143 25μm
4675
122 124 126
130 132 134
138 140 142
145 147 149 151 153 155 157 159 161 163 165 167 25μm
5350
146 148 150
154 156 158
162 164 166
8 16 40 56 72 88 104 120 136 152 168
50μm
24 32 48 64 80 96 112 128 144 160
Table B4. Tray placement for tissue sectioned non-sequential with stereology
every 8th section: for whole brain treatments or no treatment.
Place 24 well plates vertically(Section 1 here is really the 26th section)
1 97 2 98 3 99 4 100
5 101 6 102 7 103
49 145 50 146 51 147 52 148
53 149 54 150 55 151
9 105 10 106 11 107 12 108
13 109 14 110 15 111
57 153 58 154 59 155 60 156
61 157 62 158 63 159
17 113 18 114 19 115 20 116
21 117 22 118 23 119
65 161 66 162 67 163 68 164
69 165 70 166 71 167
25 121 26 122 27 123 28 124
29 125 30 126 31 127
73 169 74 170 75 171 76 172
77 173 78 174 79 175
33 129 34 130 35 131 36 132
37 133 38 134 39 135
81 177 82 178 83 179 84 180
85 181 86 182 87 183
41 137 42 138 43 139 44 140
45 141 46 142 47 143
89 185 90 186 91 187 92 188
93 189 94 190 95 191
25μm
25μm
25μm
25μm
25μm
25μm
25μm
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8 104
56 152
16 112
64 160
24 120
72 168
32 128
80 176
40 136
88 184
48 144
96 192
50μm

B4 Staining
B4.1 Background
We use free-floating sections to stain for proteins of interest in brain tissue sections.

Figure B9. Schematic of brightfield staining (Indirect).

Figure B10. Schematic of fluorescent staining (Direct).
Simply, tissue is blocked for endogenous peroxidases, cells are permeabilized
with triton, antibody for the protein of interest (known as primary antibody) is added,
antibodies towards the animal the primary antibody was grown in is added (known as
the secondary antibody).

This is precipitated out and colorized by a DAB/Nickel

reaction.
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Antibodies are produced by injecting animals with the protein/peptide which
needs to be recognized. Primary antibodies are produced by injecting a small animal
(most commonly a mouse or rabbit) with the specific protein you are interested in.
Secondary antibodies are made by injecting protein specific to the species of the
primary antibody. You will be using serum to block during multiple steps, the choice of
serum is determined by the animal the secondary antibody is grown in.
For example, a common antibody we use to recognize tau is rabbit anti-H150
tau. This is the primary antibody, which was grown in a rabbit towards tau amino acids
1-150. The secondary antibody would then be directed towards rabbit protein and also
should be tagged with a biotin, such as goat anti-rabbit BIOT. The biotin allows us to
precipitate out the complex and colorize it for staining. The serum to block with in this
example would be goat serum, since the secondary antibody was made in a goat.
To set up a stain, you will need to calculate the number of wells needed for the
stain. This will be based on the number of mice and number of sections used per
mouse, keeping in mind that whole brain tissues should be placed in the wells at 2 or
less sections per well, and half brains placed in wells at 3 sections per well or less if
possible. Also, use the small trays whenever possible to reduce reagent use. The small
trays are 8 x 5 wells (40 wells total) and use 40 mLs total of solution for each step. The
large trays are 12 x 8 (96 wells total) and use 100 mLs total solution for each step.
The choice tissue is selected based on the treatment of the mice in the cohort.
Most commonly, tissue is selected to represent the whole brain or to show the region
surrounding an injection site. This selected tissue should be added a piece at a time
and marked on the tray map (shown in Figure B11), so the tissue will not be confused.
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This should also include the date of the stain, your initials, and the concentrations of
primary and secondary antibody used, as well as any other important notes for that
stain.
Figure B11. Example tray map of tissue sections.

A characterization is done on each new antibody used for staining. This is done by
performing the stain as described in the protocol, but with using different primary
antibody concentrations. This is done by making serial dilutions of primary antibody in
PBS and serum as shown below. Use a non-treated 24 well plate with >300 µL per well,
with tissue from one mouse at one concentration of antibody per well. Load tissue
selected for no primary first, followed by loading the tissue for the other concentrations,
up to the highest concentration. The highest concentration of antibody will depend on
the manufacture’s suggestions but usually is around 1:100-1:300.
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Table B5. Antibody characterization setup
Antibody Concentration
1:300
1:1K
1:3K
1:10K
1:30K
No 1°
Additional notes:
•

PBS

Serum

1° Antibody

120 µL
84 µL
84 µL
84 µL
84 µL
84 µL

2.875 mL
1.915 mL
1.915 mL
1.915 mL
1.915 mL
1.915 mL

10 µL of Antibody
1mL of 1:300
1mL of 1:1K
1mL of 1:3K
1mL of 1:10K
No Primary

New antibodies which have not been characterized in our lab, must first be
characterized before using for a full stain.

•

Always remove sections in netted trays from liquid when moving to prevent spilling
of tissue into the wrong wells

•

Tissue can be paused at any PBS step, but it is preferable if run as listed in the
protocol. Keep trays shut/covered when pausing and put in 4C walk-in fridge if it will
be more than 24 hours.

•

Always start with PBS (or TBS) and add each ingredient to it, from least to most
expensive (typically the largest volume to the smallest volume)

•

Reagents:

L-Lysine Monohydrochloride

Fisher Cat# AC125222500

Triton-X 100

Fisher Cat# BP151-500

Goat Serum (Filtered)

Fisher Cat# 50-412-961

Donkey Serum (Filtered)

Lampire Cat# 7332100

3,3’ Diaminobenzidine tetrahydrochloride (DAB)

Sigma Cat# D5637

Nickel Ammonium Sulfate

Fisher Cat# N48-500
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Figure B12. Staining tray map blank sheet for small tray
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B4.2 Brightfield IHC protocol (Small)
1. Get a purple tray labeled wash 1 and fill with 40 mL PBS
2. Put in small netting and put in selected sections.
3. Block endogenous peroxidases:
PBS

32 mL

Methanol (shelf)

4 mL

30% H202 (4°C)

4 mL

Incubate 15 minutes at room temperature on shaker.
Remove ~6mL serum from -20°C freezer and thaw in hot water for step
*Label with today’s date, store at 4°C once thawed, use within 24 hours.
4. Wash 3x: 40 mL PBS 3x, 5 minutes each with shaking.
5. Permeabilize tissue:

·

PBS

30.4 mL

Lysine (shelf)

0.7 g

1% triton-x-100 in water (shelf)

8 mL

_________ Serum

1.6 mL

Incubate 30 minutes at RT with shaking
6. Remove control sections and place into PBS with 4% serum.
7. Primary Antibody Incubation:
38.4 mL

PBS
Serum

1.6 mL

Antibody: __________ (1:______) _____ µL
8. Cover with foil, shake for 1 hour, let incubate overnight.
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Day 2
1. Shake 60 minutes
2. Wash 3x: 40 mL PBS 3x, 5 minutes each with shaking.
3. Secondary Antibody
38.4 mL

PBS
Serum

1.6 mL

Antibody: __________ (1:______) _____ µL
Incubate for 2 hours at RT with shaking, but set a timer for 1 hour
and 45 minutes.Once timer goes off, make ABC solution (4°C): 4
drops each A and B in 40 mL PBS. Set this on a shaker to
incubate for 30 minutes, you will use this in step 5.
4. Wash 40 mL PBS 3x, 5 minutes each with shaking.
5. ABC (once conjugated for 30 minutes)
Incubate for 1 hour at RT with shaking
6. Wash 2x: 40 mL PBS 2x, 5 minutes each with shaking
7. Wash 1x: 40 mL TBS (fresh) for 5 min with shaking (if using Ni++)
8. Prepare DAB/Nickel for next step: Measure DAB and Nickel in 2 separate 50
mL tubes; get into solution <15 minutes before DAB/Nickel step. Only mix
together less than 1 minute before step 9.
9. DAB/Nickel
a. TBS (made fresh)

40 mL

b. DAB (in freezer door)

20 mg
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c. Nickel Ammonium Sulfate (shelf)

200 mg

d. Incubate 5 minutes with shaking
10. Color Development **DO NOT POUR DOWN THE SINK***
a. Remove tissue from solution
b. Add 40 µL H 2 O 2 (4°C) to DAB/Nickel solution
c. Shake for 30 seconds
d. Add tissue back into tray
e. Incubate for 5 minutes with shaking
f. Pour into liquid waste after step
11. Wash 40 mL TBS, 5 minutes
12. Wash 2x: 40 mL PBS 2x, 5 minutes each with shaking.
13. Mount tissue and allow to dry overnight, before dehydrating
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B4.3 Fluorescent protocol (Small)
1. Get a purple tray labeled wash 1 and fill with 40 mL PBS
2. Put in small netting and put in selected sections.
Remove ~6mL serum from -20°C freezer and thaw in hot water for step
5. Label with today’s date, store at 4°C once thawed.
3. Permeabilize tissue:

·

PBS

30.4 mL

Lysine (shelf)

0.7 g

1% triton-x-100 in water (shelf)

8 mL

_________ Serum

1.6 mL

Incubate 30 minutes at RT with shaking
4. Remove control sections and place into PBS with 4% serum.
5. Primary Antibody Incubation:
38.4 mL

PBS
Serum

1.6 mL

Antibody(s): __________ (1:______) _____ µL
6. Cover with foil, shake for 1 hour, let incubate overnight.
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Day 2
7. Shake 60 minutes
8. Wash 3x: 40 mL PBS 3x, 5 minutes each with shaking.
9. Secondary Antibody
38.4 mL

PBS
Serum

1.6 mL

Antibody(s): __________ (1:______) _____ µL
Incubate for 2 hours at RT with shaking.
10. Wash 40 mL PBS 3x, 5 minutes each with shaking.
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Figure B13. Staining tray map blank sheet for large tray
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B4.4 Brightfield IHC protocol (Large)
1. Get a large clear tray labeled PBS and fill with 100 mL PBS
2. Put in large netting and put in selected sections.
3. Block endogenous peroxidases:
PBS

80 mL

Methanol (shelf)

10 mL

30% H202 (4°C)

10 mL

Incubate 15 minutes at room temperature on shaker.
Remove ~12 mL serum from -20°C freezer and thaw in hot water for
step 4. Label with today’s date, store at 4°C once thawed.
3.

Wash 100 mL PBS 3x, 5 minutes each with shaking.

4 . Permeabilize tissue: ·
PBS

76 mL

Lysine (shelf)

1.83 g

1% triton-x-100 in water (shelf)

20 mL

_________ Serum

4 mL

Incubate 30 minutes at RT with shaking
5 . Remove control sections and place into PBS with 4% serum.
6.

Primary Antibody Incubation:
95 mL

PBS
Serum

4 mL

Antibody: __________ (1:______) _____ µL
7. Cover with foil, shake for 1 hour, let incubate overnight.
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Day 2
1. Shake 60 minutes
2. Wash 100 mL PBS 3x, 5 minutes each with shaking.
3. Secondary Antibody
95 mL

PBS
Serum

4 mL

Antibody: __________ (1:______) _____ µL
Incubate for 2 hours at RT with shaking, but set a timer for 1 hour and
45 minutes. Once timer goes off, make ABC solution (4°C): 8 drops
each A and B in 100 mL PBS. Set this on a shaker to incubate for 30
minutes, you will use this in step 5.
4. Wash 100 mL PBS 3x, 5 minutes each with shaking.
5. ABC (once conjugated for 30 minutes)
Incubate for 1 hour at RT with shaking
6. Wash 100 mL PBS 2x, 5 minutes each with shaking
7. Wash 100 mL TBS (fresh) 1x for 5 min with shaking (if using Ni++)
8. Prepare DAB/Nickel for next step: Measure DAB and Nickel in 2 separate 50
mL tubes; get into solution <15 minutes before DAB/Nickel step. Only mix
together <1 minute before step 9.
9. DAB/Nickel
a. TBS (made fresh)

100 mL

b. DAB (in freezer door)

50 mg

c. Nickel Ammonium Sulfate (shelf)
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500 mg

d. Incubate 5 minutes with shaking
10. Color Development **DO NOT POUR DOWN THE SINK***
a. Remove tissue from solution
b. Add 100µL H 2 O 2 (4°C) to DAB/Nickel solution
c. Shake for 30 seconds
d. Add tissue back into tray
e. Incubate for 5 minutes with shaking
f. Pour into liquid waste after step
11. Wash 100 mL TBS, 5 minutes
**Bleach tray after step
12. Wash 100 mL PBS 2x, 5 minutes each with shaking.
13. Mount tissue and allow to dry overnight, then dehydrate
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B4.5 Fluorescent protocol (Large)
1. Get a large tray labeled wash 1 and fill with 100 mL PBS
2. Put in small netting and put in selected sections.
Remove ~12 mL serum from -20°C freezer and thaw in hot water for
step *Label with today’s date, store at 4°C once thawed.
3. Permeabilize tissue:
PBS

76 mL

Lysine (shelf)

1.83 g

1% triton-x-100 in water (shelf)

20 mL

_________ Serum

4 mL

Incubate 30 minutes at RT with shaking
4. Remove control sections and place into PBS with 4% serum.
5. Primary Antibody Incubation:
95 mL

PBS
Serum

4 mL

Antibody(s): __________ (1:______) _____ µL
6. Cover with foil, shake for 1 hour, let incubate overnight.
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Day 2
7. Shake 60 minutes
8. Wash 100 mL PBS 3x, 5 minutes each with shaking.
9. Secondary Antibody KEEP AWAY FROM LIGHT FROM HERE ON
PBS

95 mL

Serum

4 mL

Antibody(s): __________ (1:______) _____ µL
Incubate for 2 hours at RT with shaking.
10. Wash 100 mL PBS 3x, 5 minutes each with shaking.
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B4.6 Characterized antibodies
Table B6. Characterized antibodies for immunohistochemistry.
°

1 Antibody

Concentration

Neu N Biotin

1:3K

2
Antibody
-

Storag
e
4°C

Goat

Company;
Catalog #
Milliopore;
MAB377BMI
Santa Cruz;
sc-1048
Santa Cruz;
Sc-1751
Thermo

Hsp27 (C-20)

1:5K

Tia1 (C-20)
AT8
(pS202,205)
12E8
(pS262,356)
CP13 (pS199,
202, 205)
HSP40

1:3K

Goat

Peter Davies

-20°C

α-Mouse

1:3K

Goat

Peter Davies

-20°C

1:100

α-Mouse

1:3K

Goat

-20°C

Hsp90-10 (90β)
MC1
(conformation)
NY18

1:300
1:10K

α-Mouse
α-Mouse

1:3K
1:3K

Goat
Goat

Stressmarq;
SPC-100D
David Toft
Peter Davies

1:10K

α-Mouse

1:3K

Goat

-20°C

P23 (JJ3)

1:600

α-Mouse

1:3K

Goat

PHF1
(pS396;404)
PHF6 (pT231)

1:5K

α-Mouse

1:3K

Goat

Lester
Binder
Fisher Sci;
MA3414
Peter Davies

1:100K

α-Mouse

1:20K

Goat

-20°C

PHF6 (pT231)

1:3K

α-Mouse

1:20K

Goat

Tau C3

1:10K

α-Mouse

1:3K

Goat

Tg3

1:300

α-Mouse

1:3K

Goat

Aβ

1:10K

α-Rabbit

1:3K

Goat

Calpain 1

1:1K

α-Rabbit

1:10K

Goat

CDC37

1:100

α-Rabbit

1:3K

Goat

FIZZ-1
GFP
GRP94

1:5K
1:1K
1:10K

α-Rabbit
α-Rabbit
α-Rabbit

Abcam;
ab24594
Abcam;
ab24594
Lester
Binder
Peter
Davies
Paul
Gottschall
Abcam;
632498
Cell Signal;
570172

1:3K
1:10K
1:10K

Goat
Goat
Goat

-20°C
-20°C

H150

1:5K

α-Rabbit

1:10K

Goat

Tau pS199-202
on rTg4510
mice

1:65K

α-Rabbit

1:3K

Goat

Invitrogen
Cell Signal;
2104S
Santa Cruz;
sc 5587
AnaSpec;
54963-025

°

Concentration

Serum

-

Goat

α-Goat

1:200

Donkey

1:2500

α-Goat

1:500

Donkey

1:5K

α-Mouse

1:3K

1:10K

α-Mouse

1:3K
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4°C
-20°C
-20°C

-20°C
-20°C

-20°C
-20°C

-20°C
-20°C
-20°C
-20°C
-20°C
-20°C

4°C
4°C

Tau pS199-202
on wild-type
mice
Tau pT212 on
wild-type mice

1:20K

α-Rabbit

1:3K

Goat

AnaSpec;
54963-025

4°C

1:1K

α-Rabbit

1:10K

Goat

AnaSpec;
54966-025

4°C

Tau pS214 on
rTg4510 mice

1:1K

α-Rabbit

1:3K

Goat

AnaSpec;
54967-025

4°C

Tau pS214 on
wild-type mice
Tau pT231 on
rTg4510 mice
Tau pS262 on
rTg4510 mice
Tau pS396 on
rTg4510 mice
Tau pS396 on
wild-type mice
Synaptophisin

1:300

α-Rabbit

1:3K

Goat

4°C

1:300

α-Rabbit

1:10K

Goat

1:1K

α-Rabbit

1:10K

Goat

1:30K

α-Rabbit

1:10K

Goat

1:5K

α-Rabbit

1:10K

Goat

AnaSpec;
54967-025
AnaSpec;
55313-025
AnaSpec;
54973
AnaSpec;
9632S
AnaSpec;
9632S

1:3K

α-Rabbit

1:10K

Goat

YM-1

1:5K

α-Rabbit

1:10K

Goat

CD 33 (M-90)

1:300

α-Rabbit

1:3K

Goat

FKBP51

1:2K

α-Rabbit

1:10K

Goat

CD3

1:10K

α-Rat

1:1K

Goat

CD4

1:30K

α-Rat

1:1K

Goat

CD8

1:30K

α-Rat

1:1K

Goat

CD45

1:10K

α-Rat

1:1K

Goat

Fc-y
CD16/CD32
HSC70

1:1K

α-Rat

1:1K

Goat

1:30K

α-Rat

1:1K

Goat

MHCII

1:5K

α-Rat

1:1K

Goat

BrdU

1:200

α-Rat

1:1K

Goat

4°C
4°C
4°C
4°C
4°C

Stem Cell
Tech; 1404
Santa Cruz;
SC-28810
Cell Signal;
8245S
AbD serotec;
MCA500GA
AbD serotec;
MCA4635GA
AbD serotec;
MCA609G
AbD Serotec;
MCA1031G
BD Bio;
553140
Stressgen;
SPA-815F
BD
Pharmigen
AbD serotec;
MCA2060T

-20°C
-20°C
-20°C
4°C
-20°C
4°C
4°C
4°C
-20°C

4°C

Biotinylated secondary antibodies are all from Southern Biotehnologies.
Swine α-Goat- IgG BIOT Cat# 3600-08, Goat α-Mouse IgG BIOT Cat# 1030-08, Goat αRabbit IgG BIOT Cat#4030-08, Goat α-Rat IgG BIOT Cat#3010-08
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Table B7. Characterized antibodies for immunofluorescence

Tau
pS199-202
Tau pS396

1:1K

2°
Alexafluor
Antibody
α-Rabbit

1:1K

α-Rabbit

1:3K

Goat

FKBP51

1:300

α-Rabbit

1:3K

Goat

Hsp27
(c-20)
Tau
(V-20)
Tau

1:1K

α-Goat

1:1K

1:50

α-Goat

1:1000

1:1K

α-Chicken

1:3K

Donke
y
Donke
y
Goat

Hsc70

1:100

α-Rat

1:3K

Goat

Streptavidin

1:3K

Goat

1:100

Streptavidin

1:1K

1:1K

1:300

α-Mouse

1:3K

Goat

1:100

α-Mouse

1:3K

Goat

1:100

α-Rabbit

1:1K

Goat

1°
Antibody

Hsc70
Biotin
NeuN
Biotin
Hsp90-10
(90β)
NeuN
GR

Concentration

Concentration

Serum

1:3K

Goat

Alexaflour secondary antibodies are all from Invitrogen.

142

Company/
Catalog #
AnaSpec;
54963-025
AnaSpec;
9632S
Cell Signal;
8245S
Santa Cruz; sc1048
Santa Cruz; sc1996
Neuromics;
CH23018
Stressgen;
SPA-815F
Abcam;
ab69558
Milliopore;
MAB377BMI
David Toft
Milliopore;
MAB377BMI
Cell Signal;
7437S

Storage
4°C
4°C
-20°C
4°C
4°C
-20°C
-20°C
-20°C
4°C
-20°C
4°C
-20°C

B4.7. Other non-standard stains:
B4.7.1 Gallyas silverstain
B4.7.1.1 Reagents
Periodic Acid

Fisher Scientific Cat# AC198401000

Potassium iodide

Sigma Cat# 746428

Sodium hydroxide

Fisher Scientific Cat# S318-3

Acetic Acid (glacial)

Fisher Scientific Cat# AC1489300010

Sodium Carbonate (anhydrous)

Sigma Cat# 223484

Ammonium nitrate

Sigma Cat# 221244

Silver nitrate

Sigma Cat# 209139

37% Formaldehyde

Sigma Cat# 252549

Tungstosilicic acid

Sigma Cat# 383341

Sodium thiosulfate

Sigma Cat#72049

Gold (III) chloride trihydrate

Sigma Cat# G4022

B4.7.1.2 Making Solutions
1. 5% Periodic Acid
1. Periodic acid

25g

2. Distilled water

500mL

2. Alkaline Silver Iodide Solution
1. sodium hydroxide

40g

2. potassium iodide

100g

3. Distilled water

500mL

4. 1% silver nitrate

35mL
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Dissolve the sodium hydroxide in water then add the potassium iodide and wait till
dissolved. Slowly add the silver nitrate and stir vigorously. Then add distilled water to
give a final volume of 1000mL
3. 0.5% Acetic Acid (need for 2 steps)
1. Glacial Acetic Acid

2.5 mL

2. Distilled water

497.5 mL

4. Stock Solution I
1. Sodium Carbonate
(Anhydrous)
2. Distilled water

50g

1000 mL

5. Stock Solution II
1. Distilled water
2. Ammonium nitrate

1000 mL
2g

3. Silver nitrate

2g

4. Tungstosilicic acid

10 g

6. Stock Solution III
1. Distilled water

1000 mL

2. Ammonium nitrate

2g

3. Silver nitrate

2g

4. Tungstosilicic acid

10 g

5. 37% Formaldehyde

7.3 mL

7. 0.1% Gold Chloride (keep from light)
1. gold chloride

1g

2. Distilled water

1000 mL
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8. 1% Sodium Thiosulfate
1. sodium thiosulfate

5g

2. Distilled water

500 mL

9. Neutral Fast Red
1. Neutral fast red
(Solution)

2mL

2. Distilled water

200 mL

B4.7.1.3 Procedure

1. Mount sections on slides and air dry overnight
2. Hydrate sections in water 30 dips
3. Place in 5% periodic acid for 5 min
4. Wash in distilled water for 2 x 5 min
5. Place in alkaline silver iodide solution for 1 min
6. Wash in 0.5% acetic acid for 10 min
Place in developer solution (Prepare immediately before use)
Add 3x Stock II to 10x Stock I. Stir, then add 7x Stock III
(i.e. 240 mL stock II, 800 mL stock I, 560 mL stock III)
***Put 3 rubber bands around slide racks, and place in leak proof container. Rock
continuously and tilt every way the entire time during this step.
Developer solution for 5-15 minutes, watch by eye and allow stain to go slightly too
dark, as it will lighten up in the following steps
8. Wash in 0.5% acetic acid for 3 min
9. Wash in distilled water for 5 minutes
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10. Place in 0.1% gold chloride for 5 min (keep from light)
11. Rinse in distilled water for 1 min
12. Place in 1% sodium thiosulphate solution for 5 min
13. Wash in tap water for 1 min
14. Incubate in filtered 1% neutral red solution (can skip this if no counterstain is
desired) for 1 min
15. Rinse in tap water 3 x 1 min
16. Dip 8 times in 95% EtOH
17. Dip 8 times 2 x 100% EtOH
18. Clear in Xylene 3 x 5 min
19. Coverslip using DPX

Tangles will be black and nuclei will be red.

146

B4.7.2 Cresyl violet (Nissl)
1. Mount sections on slides and air dry overnight
2. Hydrate sections in water 10 dips
3. Stain in 0.05% cresyl violet for 5 minutes (or less if lighter color is desired)
4. Destain in acidic water for 30 dips or until desired color
5. Rinse in water 10 dips
6. Dehydrate through graded ethanol series
75% EtOH 30 dips
95% EtOH 30 dips
100% EtOH 30 dips
7. Clear in histoclear, 3 x 5 min each
8. Coverslip with DPX
9. Filter Cresyl violet solution after use
10. Rinse out blue ethanols and remake

Solutions:
Cresyl Violet: 0.05% in water, pH 3.3 with acetic acid
Add 0.25g dye to 500mL water, stir 1 hour and adjust pH
Keep from light
Acidic Water: 6 drops acetic acid per 200mL water
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B4.7.3 Hematoxylin (Nuclei) and eosin (cytoplasm)
1. Mount tissue and allow to dry over night
2. Rehydrate in ddH 2 O
3. While sections are in water, filter hematoxaline and pour into dish. Skim surface
of hematoxalin with a Kimwipe to remove oxidized particles. Blot excess water
from slide holder before going into hematoxalin
4. Incubate in hematoxalin for 3 minutes.
5. Rinse in ddH 2 O for 30 sec
6. Wash in tap water for 5 minutes (to allow stain to develop)
7. Dip quickly 8-12x times in acid ethanol (to destain)
a. 151.65 mL 95% EtOH
b. 55.88 ddH 2 O
c. 0.529 HCl (conc.)
8. Rinse 2x in tap water for 1 minute
9. Blue in 0.2% ammonia Water solution
a. 400uL ammonium hydroxide conc. per 200mL ddH 2 O
10. Rinse 1 time in ddH 2 O for 2 minutes (can leave overnight if needed at this
stage)
11. Blot excess water from slide holder on paper towel
12. Incubate in Eosin solution for 10 seconds (older solutions may take up to 45
seconds)
a. 2.5g eosin
b. 495 mL H 2 O
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c. 0.5 mL glacial acetic acid
13. Dehydrate in 95% EtOH 3x for 5 minutes
14. Dehydrate in 100% EtOH 3x for 5 minutes
15. Clear in Xylenes 3x for 5 minutes
16. Coverslip with DPX
17. Lay slides flat on a tray and allow to dry overnight
***Eosin can interfere with other stains, so dishware should be labeled for only this
purpose
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B4.7.4 Prussian Blue (Iron stain for microhemorrhage)
***Make neutral red solution the night before
***Steps 1-5, glassware needs to be clean and to not have any tap water, this
contains iron which will affect the reaction
***Prolonged washing in water and ethanol will reduce the neutral red staining
1. Mount sections on slides and air dry overnight
2. In separate containers make:
a. 2 mL conc. HCl + 98 mL ddH 2 O
b. 2g potassium ferrocyanide + 100 mL ddH 2 O
3. Mix a and b. immediately before use
4. Rehydrate sections in distilled water for 30 seconds
5. Incubate in a. and b. mixture for 15 minutes
6. Rinse two times in distilled water for 30 seconds
7. Rinse once in tap water for 5 minutes
8. Rinse slides in ddH 2 O for 30 seconds
9. Incubate in filtered 1% neutral red solution for 1 minute
a. 2g neutral red
b. 200 mL ddH 2 O
10. Rinse through three changes of tap water for 1 minute each
11. Dip 8 times in 95% EtOH
12. Dip 8 tims through 2 changes of 100% EtOH
13. Clear in xylenex 3x for 5 minutes each
14. Coverslip with DPX
15. Lay on tray and allow to dry overnight
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B4.7.5 NeuroTrace® 640 (Flourescent Nissl Stain)
Modified from datasheet by Moleular probes CAT # N21483
Stored in -20C
1. Mount after antibody stain and let sit overnight.
2. Rehydrate slide in PBS for 40 minutes.
3. Wash in 0.1% Triton-X+PBS for 10 minutes
4. Wash 2x in PBS for 5 minutes.
5. Dilute Neurotrace 1:25 in PBS.
6. Apply 200 uL to cover each section for 20 minutes.
7. Wash in 0.1% Triton-X for 10 minutes.
8. Wash 2x in PBS for 5 minutes.
9. Coverslip
10. Store at 4◦
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B4.7.6 Thioflavin S
1. Mount sections on slides and air dry over night
2. Hydrate sections in ddH 2 O for ~30 seconds
3. Blot rack on paper towel
4. Stain in Mayer’s hematoxylin for 2 minutes (to block nuclear fluorescence
and establish a background)- this solution is reusable and should be
filtered
5. To convert red hematoxylin to blue, place slides in ammonia water (10
drops NH 4 OH conc. in 200 mL ddH 2 O for ~30 sec)
6. Rinse in ddH 2 O for 3 minutes
7. Rinse two more times in ddH 2 O for 2 minutes each
8. Turn off lights or work in dim lighting
9. Stain sections for 10 minutes in a 1% Thioflavine-S solution (2g ThS in
200 mL ddH 2 O).
10. Wash in ddH 2 O two times for 30 seconds each
11. Wash in 75% EtOH for 30 seconds
12. Dehydrate in 100% EtOH for 1 minutes (any longer will destain)
13. Clear in xylenes 3x for 5 minutes each
14. Coverslip

with

DPX

and
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allow

to

dry

on

tray

overnight.

B4.7.7 Β-Galactosidase stain
Day 1
1. Prepare staining solution
a. Dilute one part 100x X-Gal solution with 99 parts staining buffer
i. (*24 well plate—total volume = 6 mL – prepare 7 mL
ii. 6.93 mL staining buffer
iii. 70 μL X-Gal Solution
b. Add 0.02% NP40 and 0.01% DOC into staining solution
i. 140 μL NP40
ii. 70 μL DOC
2. Add staining solution to tissue culture dish
i. 0.25 mL per well
3. Add sections to tissue culture dish
4. Incubate sections overnight at 37ºC
Day 2
1. Remove dish from heat
2. Prepare 1x PBS by diluting 1 part 10x PBS with 9 parts diH 2 0
a. (*24 well plate—total volume = 40 mL = 0.5mL/ well
b. 36 mL diH 2 0
c. 4 mL 10x PBS
3. Add 1x PBS to new tissue culture dish
4. Add sections to 1x PBS, wash 5 min
5. Repeat 3x
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B4.7.8 Sudan Black (for fluorescent staining of tissue with high background)
After staining and counterstaining are complete:
1. Incubate tissue in 0.1% Sudan Black B solution in 70% EtOH for 20
minutes
a. 40 mg in 40 mL
b. 100 mg in 100 mL
2. Wash with PBS + 0.02% Tween-20 4x for 5 minutes each
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B4.7.9 BrdU immunostaining protocol
***Mice must first be given BrdU via IP or drinking water.
1. 20 min 3% H 2 O 2 – only if DAB (blocks endogenous peroxidase in blood)
2. PB wash, 2x – 5-10 min
3. 1 hour incubation @ 55°C: 50% Formamide, 50% 4x SSC
4. Rapid wash sections in 2x SSC (opens DNA strands)
5. 30 min incubation in 2N HCl @ 37°C
a. 6.68 mL conc HCl in 40 mL PBS
6. 0.1M Boric Acid wash (neutralize 2N HCl), 2 min
a. 0.2472g in 40 mL PBS
7. PBS wash, 3x – 5-10 min
***If desired, can continue with normal staining process from this point on; start at
permeablilization step***
8. 1 hour incubation in blocking solution
90% PBS-Tx 0.25%, 10% Goat Serum
9. Overnight incubation in primary anitbody in cold room.
Rat anti-BrdU, 1:200 in blocking solution AbD Serotec #MCA2060T
10. PBS wash, 3x – 5-10min
11. 1 hour incubation in Secondary Antibody @ room temp.
*Biotinlyated goat anti-rat IgG, 1:200 in blocking solution
12. PBS wash, 3x – 5-10min
13. 45 minute incubation in ABC (Avidin-Biotin Complex)
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*Prepare ABC 30-45 minutes before usage. Use different pipette tip for each
component to avoid contamination of stock solutions.
*1:300 A, 1:300 B in 0.1M PB
14. PBS wash, 4x – 5-10min (minimize background)
15. DAB (until sections begin to turn brown) inside hood
*Solution Prep: 1 mL DAB in 60 mL PB (-80°C Freezer). Add 100 µl H 2 O 2 right
before addition to sections
*Filter DAB solution as adding to sections
*Use bleach to clean/dispose of DAB
16. Rapid wash w/ dH2O (4°C)
17. PBS wash, 3x – 5-10min
18. Keep sections in foil at 4°C until mounting
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B4.7.10 Congo red
1. Mount slides and dry overnight

2. Clean 9 glass dishes and label:
o

diH2O

o

Alkaline Sodium Chloride Solution

o

Congo

o

95% EtOH

o

100% EtOH

o

100% EtOH

o

Prepare 3 Xylene

3. Hydrate in diH2Ofor 10 dips
4. Incubate in Alkaline Sodium Chloride for 20 minutes
(Just prior to use add 2 mL NaOH to 198 mL Sat. Alcoholic Sodium Chloride)
5. Congo Red- 15 minutes
a. Make within 15 minutes of use
b. Add 2 mL 1M NaOH to 198 mL Congo
c. Filter solution
d. Clean glassware immediately
6. 1X 95% EtOH for 3 dips
7. 2X 100% EtOH for 3 dips
8. 3X Xylene for 5 minutes each
9. Coverslip with DPX
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B5. Mounting tissue

Figure B14. Example of mounted tissue
1.

Label slides using a hard, number 3 pencil with Mouse study name/number,
stain, initials and date as shown above.

a.

This can be done ahead of time!

2.

Turn on light source, as this will help you see folds.

3.

Put a white paper towel or Kim wipe down if the tissue is stained, and use the
black countertop if the tissue is not stained or very lightly stained.

4.

Using a paintbrush, mount tissue onto charged glass slides in mounting
solution.

5.

Do not mount tissue at the very top of the slide, because the slide scanning
microscope cannot image this region (shown above).

6.

Mount sections straight, flat, and without tears or folds

7.

Mount whole slices in mounting solution with the notch on the left.
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8.

Mount half brains in mounting solution as the left hemisphere.

9.

Mount tissue in order from top to the bottom horizontally through the brain.
(just as it would come off in order as you section) Make sure you mount in
straight lines, as this will help save a lot of time on the imaging and analysis
of the stain.

10.

Daub on a paper towel after you get each section on. This pulls off water
and helps the tissue stay on the slide better when submerged again in
mounting solution to do the next piece.

11.

Dry vertically, propped against something, with the bottom on a paper towel.

12.

Once dry, lay out flat on a tray overnight.

13.

Dehydrate the next day.

14.

If dehydrating will be more than 48 hours away, cover to keep dust off the
slides.
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B6. Dehydrating and coverslipping for brightfield stains

FigureB15. Dehydration dunker set-up.
1.

Put slides like an accordion into movable glass rack (fits 19 as shown in Figure
B14).

2.

Be careful, the metal handle comes out!

3.

Rehydrate tissue in clean, fresh ddH 2 0 for 3 minutes.

4.

Tilt rack sideways to remove as much water as possible, before moving to the
next step, and each of the following steps. Dunk a couple times when first placing
in the next step.

5.

3 minutes in 25% Ethanol

6.

3 minutes in 25% Ethanol

7.

3 minutes in 50% Ethanol

8.

3 minutes in 50% Ethanol

9.

3 minutes in 75% Ethanol

10.

3 minutes in 75% Ethanol

11.

5 minutes in 95% Ethanol

12.

5 minutes in 95% Ethanol

13.

5 minutes in 95% Ethanol

14.

5 minutes in 100% Ethanol
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15.

5 minutes in 100% Ethanol

16.

5 minutes in 100% Ethanol (change final 100% EtOH each time, rotate with the
other two 100% EtOH containers, so they are all periodically being changed)

17.

5 minutes in Histoclear (check clarity of slides, oily looking is normal, water
droplets are not. If oily put back in 100% EtOH dunking 15 times followed by 3
minutes)

18.

5 minutes in Histoclear

19.

5 minutes in Histoclear

20.

Leave rack and slides in Histoclear, remove one slide at a time. Do not let slides
dry out before coverslipped.

21.

Drip 3 drops of DPX down slide using a glass stir rod.

22.

Angle the coverslip and let fall gently onto the slide. Allow DPX to spread
beneath the coverslip, covering all the tissue. Remove ALL bubbles using a Qtip.

23.

Lay coverslipped slides flat on paper towels and dry overnight.

24.

Clean glass rod well and throw out Q-tip.

25.

After dried, scrape slides clean using a razor blade and wipe with Kimwipes.

26.

Slides should be placed in the appropriate slide box for long-term storage.

27.

Make sure to dump out dd 2 0 and turn over to dry.

Histoclear can be purchased from Fisher Scientific Cat# 50-899-90147.
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B7. Analysis of staining
B7.1 Drawing regions of interest
1. Use program Zeiss NeuroQuant IAE-STI
This program can be installed and used on any Window OS.

Figure B16. Explanation of IAE-STI (A) Open TIFF file and set (B) magnification to 610X. Click on (C) the yellow roundish icon to draw region and (D) label the region. Click
on (E) the red roundish icon to draw areas within the yellow region that should be
excluded. Use (F) the cursor to remove single points. Use (G) the subtract points
function to remove multiple points from the yellow region at one time. (H) Save file when
finished.
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2. Open the tif file (Figure B15A) associated with the slide you want to outline, not
the folder.
3. Zoom to ~6X magnification (Figure B15B). Ideally you should be somewhere
between 3-10X magnification, the most important thing is that you are consistent
between all the samples you are processing for the analysis. It helps to have it
so the whole structure you are trying to outline is taking up most of your screen.
4. Click on the yellow roundish icon (Figure B15C).
5. Using left clicks, trace the region of interest (ROI) you are trying to analyze.
a. If you need to move to be able to trace the entirety of the structure you are
outlining, be sure to use the arrows on the slides at the bottom of the
screen. Don’t use the scroll wheel as that will alter the zoom.
b. You will be able to correct this once you have the region outlined.
6. Once your ROI is traced, right click to close the ROI. It should highlight bright
yellow. Label the region (Figure B15D) with a region initial and mouse number.
7. If there are any obvious folds, tears, holes, etc you can exclude them from the
ROI. Use the red roundish button (Figure B15E), and in the same manner as the
initial tracing, left-click around whatever needs to be excluded. Right click to
enclose the red region. This region does not need to be labelled.
8. To adjust the yellow area, click the cursor icon (Figure B15F) to adjust single
points or the subtract region icon (Figure B15G) for multiple points. Make sure
the yellow region is selected, which will show red dots around the region.
9. Once you’ve traced an ROI, press the save button (Figure B15H).
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B7.2 Creating a segmentation file (Threshold positive stain)
To analyze files double click Zeiss NeuroQuant IAE-STI on the desktop
1. Open the tif file of a medium/dark stained image from the stain.

Figure B17. Setting up a segmentation file in IAE-STI. Zoom in to (A) 1:1 ratio in an
area of positive staining. Select (B) the hand cursor and right click on the positive stain
(C). Use Visualize and clear/toggle to see the segmentation and region of interest
respectively. Adjust the (F) VAL Range, (G) Saturation, and (H) Hue as needed. (I)
Filter by area to remove dust and dirt. (J) Save and (K) load segmentation files.
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2. Zoom to 1:1 (Figure B16A) view on dark staining
3. Select the “hand” cursor (Figure B16B).
4. Right Click on positive stain (Figure B16C) until satisfied with the threshold of
staining, click “Visualize” to update on image.
5. Clicking ”Visualize”/”Clear/Toggle” (Figure B16, D-E) goes between segmentation
and regions of interest
6. Adjust “VAL Range”, “Saturation”, and “Hue” (Figure B16, F-H) until satisfied, to
filter out small dust/ dirt particles
7. Adjust “Filter by Area” (Figure B16I) until smaller dust/ dirt are removed from
analysis.
8. Save the segmentation file by clicking “Save” (Figure B16J).

Name the

segmentation file and save into a “Segmentation” folder you have made. File
extension is: *.iae .
9. To load a saved segmentation file press “Load” (Figure B16K) in segmentation
panel. Find the file, press open.
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B7.3 To Analyze saved images with regional IDs
1. Go to File on Menu bar
2. Select “Batch Process”
3. Click “Add Files…”
a. Find the folder where the images are located
b. Select only the ones with drawn areas (can be seen if you change file type
to all)
c. Click OK
4. Check Combine Output to 1 CSV file – Name the file to be saved and save it in
the segmentation folder which also has the segmentation file, to keep everything
organized
5. Load the segmentation(*.iae) file under “User Color segmentation”
6. Press “Begin”
7. Analysis may take over night to process depending on the number of files you
have and the areas that you are analyzing.

Figure B18. Setting up batch process in IAE-STI.
8. Once analysis is complete locate the .CSV file and convert to a .XLS for analysis
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B7.4 Quantify the results
1. First save .CSV file as Excel workbook, by Save As… Excel Workbook
2. Sort by column B and only average regions which are labeled in this
column, not including those labelled “TOTAL” in column A.
3. Average the area ratios of each mouse for the region
4. Standard deviations, ttests and standard errors should come from the
averaged numbers of each group
5. N should correspond to the number of mice

Excel formulas:
Formulas
Average

=average()

standard
=stdev()
deviation
standard error

=stdev/(sqrt(count(N-1))

ttest

=ttest(avg1,avg2,2,3)

count

=count(N)
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B7.5 Representative images
B7.5.1 Representative images using Mirax viewer
Find the sections which best represent the results and convert scanned slide to a single
image by using the Mirax Viewer or by using Mirax2Axiovision.
1. Using Mirax Viewer (Can be installed on any computer):
2. Draw regions needing to be exported inside a box by clicking on the box icon and

drawing a box around the region of interest:

Figure B19. Drawing a region to exprot in mirax viewer.
3. Then export using: File>Slide Export>

Figure B20. Exproting a region in Mirax viewer.
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a. The higher magnification you need the region, the higher the til e size ratio
you should pick. Use a consitant ratio for representative images that are
going to be used in one figure panel.
b. Add the caption regions to the right side, which shows what is going to be
exported.
4. To draw a scale bar, you can do so by clicking creat distance measurement

Figure B21. Creating a scale bar in Mirax viewer.
a. When exporting, make sure to “Burn in annotations” to export with the
scale bar

Figure B22. Exporting a region with a scale bar in Mirax viewer.
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B7.5.2 Representative images using Using Mirax2AxioVison batch processing
(Can be installed on any Windos OS computer):
1. Add Mirax files to be converted (*.mrxs).
2. Set the Image layer resolution to “4” – four will always work. 3 can be hit or miss, so
it’s best to stick with 4 so the program is not super grumpy.
3. Set tile size to “Single Image.”
4. Designate the output directory—useful to designate a separate folder for the images
to go in.
5. Press begin.
a. It may pop up warnings that the file outputs will be large, just press ok.

Figure B22. Exporting whole slide images using Mirax2Axiovision
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B8 Solutions
B8.1 Normal saline (NaCl 0.9%)
1. Sodium Chloride (NaCl) – 18g
2. Fill to 2000 mL ddH 2 0
3. Stored at room temperature
4. no need to pH
5. Filter before use
6. Store at RT

B8.2 Mounting solution
1. 200 mL ddH 2 0
2. 100 mL PBS
3. 100 mL 95% ethanol
4. Store at RT on staining bench
5. Filter after each use
6. Remake when tissue sinks to the bottom quickly
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B8.3 PBS
1. Sodium chloride (NaCl) – 16.0g
2. Sodium Phosphate Dibasic Anhydrous (Na 2 HPO 4 )- 2.3g
3. Potassium chloride (KCl)– 0.4g
4. Potassium phosphate (KH 2 PO 4 )– 0.4g
5. Fill to 2000mL ddH 2 0
6. pH 7.4
7. Filter before use
8. store at RT

B8.4 SPB 2X
1. Potassium phosphate (KH 2 PO 4 )– 8.06g
2. Sodium Phosphate Dibasic Anhydrous (Na 2 HPO 4 )- 20.0 g
3. Fill to 1000mL ddH 2 0
4. pH 7.4
5. Store in 4°C deli fridge
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B8.5 4% Paraformaldehyde solution
6. Make within 48 hours of use
7. Make 10-20 mL/brain vial
8. Add 10g PFA in 100 mL ddH 2 0 to make a starting 10% solution
9. Put in a flask with a stirbar
10. Heat and stir on a hotplate in hood at speed 1 and bring to 60°C with thermometer
11. Maintain 60°C for 5 minutes
12. While hot, Add NaOH (conc.) until clear (about 8 drops of concentrated solution)
13. Cool to room temperature
14. Add 125 mL of SPB 2x
15. pH 7.4
16. Bring final volume to 250 mL with ddH 2 0
17. Filter
18. Store in 4°C deli fridge

PFA

Starting ddH 2 0

NaOH

SPB 2x

Fill to with ddH 2 0

4g

40 mL

~3 drops

50 mL

100 mL

10 g

100 mL

~8 drops

125 mL

250 mL

20 g

200 mL

~16 drops

250 mL

500 mL
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B8.6 Dehydration solutions
1. 25% : 116 mL 95% ethanol + 324 ddH 2 0
2. 50% : 232 mL 95% ethanol + 202 ddH 2 0
3. 75% : 347 mL 95% ethanol + 93 ddH 2 0
4. 95% larger bottles
5. 100% smaller bottles
6. Put 220 mL in each dish
7. Always use 95% EtOH to make dilutions

B8.7 DPBS + Azide
1. Start with PBS

2. CaCl

3. MgCl

4. Sodium Azide

500 mL

0.068 g

0.025 g

0.325 g

1000 mL

0.125 g

0.05 g

0.65 g

2000 mL

0.27 g

0.1 g

1.3 g

5. Keep CaCl and MgCl containers closed as much as possible, they absorb a lot of
moisture from the air
6. Make sure solution is still clear!
7. Final pH 7.4
8. Filter before use
9. Chill before use, store in 4°C deli fridge
10. Re-pH each time before using, this solution can sometime change pH
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B8.8 TBS
1. ddH 2 0

2. Tris base

3. NaCl

4. HCl (10N)

125 mL

0.75 g

1.1 g

0.4688 mL

250 mL

1.5 g

2.2 g

0.9375 mL

300 mL

1.8 g

2.64 g

1.125 mL

500mL

3.0 g

4.4 g

1.875 mL

600 mL

3.6 g

5.28 g

2.25 mL

5. Filter before using
6. Store at RT
7. Final pH 7.6

B8.9 Sucrose
Volume

%

1. ddH 2 0

2. Sucrose

3. SPB 2X

500 mL

10%

487.5 mL

50 g

12.5 mL

1000mL

10%

975 mL

100 g

25.0 mL

500 mL

20%

487.5 mL

100 g

12.5 mL

1000mL

20%

975 mL

200 g

25.0 mL

500 mL

30%

487.5 mL

150 g

12.5 mL

1000mL

30%

975 mL

300 g

25.0 mL

4. Store in 4°C
Check solution for mold before using on tissue
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APPENDIX C:
ADDITIONAL PROTOCOLS

C1.1 Sarkosyl insoluble protocol for rTg4510 mice
1. Weight Brain, keep @ -80C as much as possible
a. Weigh with utensils that have been chilled in dry ice and clean with EtOH
between samples
2. Use 10x the volume of homogenization buffer to homogenize brain (10uL = 1mg)
a.

Homogenize with dental tool or homogenizer at speed 5-6 (if over 1 mL of
buffer needs to be used to homogenize bit, use 5mL tubes). Keep on ice,
homogenize right away on ice. Do one sample at a time, not leaving the
bit in buffer for more than a few seconds before homogenizing.
Homogenize each sample for the same amount of time. Usually 30
seconds to 1 minute is sufficient for most samples.

b.

If sonication is needed, sonicate for 20 pulses. If not proceed to the step 3.

3. Low-speed spin (LSS):
a.

Ultracentrifuge homogenate @ 13,000 x g for 15 minutes at 4ºC.

4. Transfer supernatant to a new 1.5 mL tube, label this new tube LSS, Run BCA
Protein assay on LSS. Keep at -80ºC.
5. Take 400 µg of protein to start P3 fraction
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a. You can start with as little as 200 µg from adult rTg4510 mice, but adjust
the rest of the steps for any changes in starting protein amount.
b. Make sure all the volumes are equal.
1. Ultracentrifuge homogenate @ 100,000 x g for 23 minutes at 4ºC (or 150,000xg
for 15 min)
a. Make sure you are using 100,000 x g tubes
1. Transfer supernatant to a new 1.5 mL tube, label S1, run BCA, keep at -80ºC
1. Homogenize pellet with 300uL Buffer B by using dental tool
1. Ultracentrifuge Buffer B homogenate @ 100,000 x g for 23 minutes at 4ºC (or
150,000xg for 15 min)
2. Make sure you are using 100,000 x g tubes
1. Keep P2 pellet in -80C, incubate supernatant with 1% Sarkosyl (final
concentration) at 37ºC for 1 hour.
a. Use 10% stock Sarkosyl Buffer
b. 11 uL of 10% Sarkosyl for each 100uL solution = final concentration of 1%
Sarkosyl solution
1. Ultracentrifuge @ 100,000 x g for 45 minutes at 4ºC (or 150,000 x g for 30 min)
a. Circle the around where the pellet should be
b. The pellet will be invisible
1. Transfer supernatant, from the opposite side of the tube from the pellet, to a new
1.5 mL tube, label S2, keep at -80ºC
1. Re-suspend Pellet in TE Buffer using dental tool in circle region
a. 2 ul TE buffer = 1 mg brain
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15. Perform protein assay for S1 to determine protein concentration
16. Run Westerns by using 3uL P3 and 2ug per sample of the S1 fraction.
C1.2 Solutions for Sarkosyl insoluble preparation
C1.2.1 Homogenization buffer:
1/100 dilution (10uL per 1mL of Hsaio TBS)
o

Protease inhibitor for tissue from Sigma (keep at -20C)

o

Phosphatase inhibitor Cocktail I (keep at 4C) (or Phosphatase inhibitor
Cocktail 3 can be used)

o

Phosphatase inhibitor Cocktail II (keep at 4)

o

PMSF (100mM)

o

With Hsaio TBS

C1.2.2 Buffer B:
10mM Tris, pH 7.4
0.8M NaCl
10% Sucrose
1mM EGTA
1mM PMSF
(can make up stocks without PMSF and store at 4ºC, then just add PMSF when
needed)
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To make 3.75 mL Buffer B use:
o

1mL 3M NaCl

o

0.75mL 50% Sucrose

o

37.5uL 1M Tris pH 7.4

o

37.5 uL 100mM EGTA

o

37.5uL 100mM PMSF

o

1.89 mL dH2O

C1.2.2 Hsiao TBS:
o

500ml

o

50mM Tris Base (3g)

o

274mM NaCl (8g)

o

5mM KCl (0.2g)

o

PH=8.0

Can make a stock and store at 4°C.
Use this buffer to dilute samples for westerns
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C2. DNA isolation from tissue using QG-Mini80
C2.1 DNA isolation using QuickGene DNA Tissue Kit S
1. Reagents
a. MDT-Tissue lysis buffer
i. Store at RT
ii. Shake before use
iii. If precipitates form, heat to 55°C and cool to RT before use
b. EDT- Proteinase K
i. Keep at 4°C
c. LDT- lysis buffer
i. Store at RT
ii. Shake before use
iii. If precipitates form, heat to 37°C and cool to RT before use
d. WDT- wash buffer
i. Store at RT
ii. Supplied as concentrate, add 160 mL of 100% EtOH before first use
and check box
iii. Close the lid tightly so EtOH does not evaporate after use
e. CDT- elution buffer
i. Store at RT
ii. Shake before use
f. RNase buffer
i. This does not come with kit and will need to be purchased separately
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ii. Make sure the RNase buffer does not have DNase activity or it will
need to be heat inactivated
2. Weigh out 10-15 mg of frozen tissue into an RNase/DNase free 1.5 mL tube.
a. Add 180 µL MDT
b. Add 20 µL EDT
3. Incubate at 70°C overnight, until tissue is completely lysed (use 55°C if isolating
DNA from tail tissue)
a. Lysis should continue for about 16 hours
b. Can be extended if samples are not fully lysed
4. Once lysed, spin at 8,000 x g (10,000 rpm) for 3 minutes at RT
a. Do this 8 samples at a time if continuing to purification using QG-Mini80
5. Transfer supernatant into a new RNase/DNase free 1.5 mL tube
6. Treat with RNase 20 µL of 20 mg/mL is sufficient for 15 mg samples.
a. Vortex for 5 seconds
b. Flash spin down
c. Incubate at RT for 2 minutes
7. Add 180 µL LDT
a. Vortex for 15 seconds
b. Flash spin down
8. Incubate at 70°C for 10 minutes
a. Flash spin down
9. Add 240 µL of 100% EtOH
a. Vortex for 15 seconds
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b. Flash spin down
10. This is your lysate; continue to purification right after this step.
C2.2 DNA purification using QG-Mini80
1. Set up the machine
a. Put waste tubes in apparatus
b. Make sure tube adaptors are in place, and add in collection tubes
c. Insert cartridge holder into the wash position (closest to you, should be
able to see WASH label)
d. Add cartridges to the holder
2. Transfer each lysate into a separate cartridge
3. Apply pressure using QG-Mini80
4. Wash each sample with 750 µL WDT
5. Apply pressure using QG-Mini80
6. Wash each sample with 750 µL WDT
7. Apply pressure using QG-Mini80
8. Wash each sample with 750 µL WDT
9. Apply pressure using QG-Mini80
10. Move cartridge holder into the elution position (furthest from you, should not be
able to WASH label)
11. Add 200 µL CDT
a. Incubate 90 seconds at RT
12. Apply pressure using QG-Mini80
13. This is your purified genomic DNA. Cap and label tubes.
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